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Abstract 
Hairpin pyrrole-imdazole polyamides are cell-permeable, sequence-programmable 
oligomers that bind in the minor groove of DNA. This thesis describes studies of Py-Im 
polyamides targeted to biologically important DNA repeat sequences for the purpose of 
modulating disease states. Design of a hairpin polyamide that binds the CG dyad, a site of 
DNA methylation that can become dysregulated in cancer, is described. We report the 
synthesis of a DNA methylation antagonist, its sequence specificity and affinity informed 
by Bind-n-Seq and iteratively designed, which improves inhibitory activity in a cell-free 
assay by 1000-fold to low nanomolar IC50. Additionally, a hairpin polyamide targeted to 
the telomeric sequence is found to trigger a slow necrotic-type cell death with the release 
of inflammatory molecules in a model of B cell lymphoma. The effects of the polyamide 
are unique in this class of oligomers; its effects are characterized and a functional assay 
of phagocytosis by macrophages is described. Additionally, hairpin polyamides targeted 
to pathologically expanded CTG•CAG triplet repeat DNA sequences, the molecular 
cause of myotonic dystrophy type 1, are synthesized and assessed for toxicity. Lastly, 
ChIP-seq of Hypoxia-Inducible Factor is performed under hypoxia-induced conditions. 
The study results show that ChIP-seq can be employed to study the genome-wide 
perturbation of Hypoxia-Inducible Factor occupancy by a Py-Im polyamide. 
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1.1  Complexity coded in DNA 
The blueprint for living organisms encoded in deoxyribose nucleic acid (DNA) 
determines every possible transcriptomic and proteomic state for all the cells in an 
organism. According to the central dogma of molecular biology put forth in 1958, DNA 
is the foundational molecule from which ribonucleic acid (RNA) is transcribed, and 
protein is translated from the RNA transcript (Figure 1.1A).1 The coordination and 
control of these molecules are critical to the spatiotemporal organization of cell activity 
and tissue maintenance in organismal health. In humans, the 3 billion letter genome is 
organized in 23 chromosomes and encodes over 20,000 protein-coding genes.2 In 
addition, over 15,000 long non-coding RNA transcripts have been identified and are 
thought to play a regulatory role.3 The structural organization of DNA and its gene 
expression profile is specific to each cell-type and is accomplished by layers of 
exquisitely controlled processes. The etiology of many diseases can be found in 
misregulated DNA. Modulation by chemical means of DNA regulation may yield 
strategies for therapeutic benefit. 
 
1.2  Epigenetic Organization of DNA 
Eukaryotic DNA is condensed and regulated as chromatin to expose appropriate 
genes for transcription and maintain genome integrity in the face of a genotoxic 
environment (Figure 1.1A). The fundamental unit of organization is the nucleosome core 
particle, a histone octamer protein assembly wrapped by 147 base pairs of DNA (Figure 
1.1B).4 The wrapped DNA can be compacted densely into heterochromatin, which is less  
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Figure 1.1  Structural organization of DNA in the cell. A) DNA (in black) is wrapped around the 
nucleosome core particle and organized as compact heterochromatin or transcriptionally active 
euchromatin. Transcription factors (TF) bind DNA and recruit cofactors (CF) and RNA 
polymerase II (RNAP) to transcribe mRNA from DNA. mRNA is translated into protein by 
ribosomes.  B) The nucleosome core particle is comprised 147 base pairs of DNA wrapped 
around a histone octamer. Epigenetic modifications, including methylation (Me), acetylation 
(Ac), ubiquitiniylation, and SUMO-lation on the tails of histones govern chromatin structure. 
Methylated DNA is recognized by methyl-binding proteins (MBP) which recruit histone 
deacetylases (HDAC) to modify chromatin into a transcriptionally inactive state. C) 
Chromosomes end in the telomeric 5’-TTAGGG-3’ hexamer repeat sequence, which can trigger a 
DNA damage response due to its similarity to a DNA double-stranded break. Telomeres form a 
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loop structure with invasion by the 5’ strand to conceal the DNA end. TRF1 and TRF2 bind the 
telomere sequence and POT1 stabilizes the single-stranded DNA. 
 
accessible for transcription and the requisite transcription machinery. Alternatively it can 
be packed more sparsely into euchromatin, which is a more transcriptionally active 
structure. The regulation of chromatin structure occurs by chemical annotation of the 
histones and DNA at the associated loci.5 Histones can be methylated, acetylated, 
ubiquitinylated, phosphorylated, and SUMO-lated to modulate transcription or to respond 
to genotoxic stress. Proteins bound to enhancers modify, or recruit other enzymes that 
modify, the proximal histones that determine the transcriptional landscape of the cells. 
These epigenetic modifications are heritable and strongly correlate with the 
transcriptional programs that determine cell fate.6 The key element of the epigenetic code 
on mammalian DNA is the methylation of the 5’ carbon of cytosines in the palindromic 
CG dyad. This two base pair motif is concentrated in sequences called CpG islands, often 
associated with promoter sites.7 The methylation of these CpG islands is transcriptionally 
repressive; methylated cytosines are bound by methyl binding proteins which recruit 
histone modifying enzymes to annotate the proximal histones into transcriptionally 
repressive heterochromatin (Figure 1.1B).8 In this manner, DNA is purposefully 
structured and regulated for function. 
 
 In this organization of DNA, chromosome ends present a danger of being detected 
as DNA double-stranded breaks. Histones are sensitive to DNA damage and become 
phosphorylated upon detection of double stranded breaks, signaling towards repair or cell 
death.9 To resolve the “end-protection problem”, nature provides a structural solution.10 
The telomere is comprised of 6- base pair repeats of 5’-TTAGGG-3’ spanning 5-30 
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kilobases with a 5’ single strand overhang.10 The repeating overhang is looped back to 
invade the double-stranded repeat region (Figure 1.1C).11 The sequence repetition ensures 
complementarity and the end is hidden in the loop. Proteins including TRF1 and TRF2 of 
the shelterin complex, as well as POT1, which binds the single stranded portion, clamp 
this structure together.11 The maintenance of this structure is important to maintain 
genome integrity, as its disruption is known to cause genotoxic stress signals and 
deleterious recombination.12 
 
1.3  Transcriptional Regulation  
In the context of this regulated DNA structure, transcription is enabled when 
transcription factor proteins bind enhancer regions coded in the DNA sequence. 
Transcription factors are proteins that bind DNA in a sequence-specific manner and 
function to either activate or repress transcription.13 The enhancers of genes under a 
transcription factor’s control contain the conserved cognate binding sequence for the 
protein. Transcription factors achieve specificity through their DNA binding domains 
(DBD). There are several conserved structural motifs for DNA binding and they include 
basic-helix-loop-helix, zinc finger, and high mobility group box DBDs (Figure 1.2).14-16 
These DBDs are linked to protein domains that transactivate transcription. 
 
In mammals, these transcription factors do not bind in isolation but bind 
cooperatively to recruit cofactors and the RNA Polymerase II machinery to the 
transcription start site. The assemblage of multiple factors integrates various signaling 
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Figure 1.2  Crystal structures of transcription 
factors bound to DNA. DNA binding domains of 
transcription factors fall into several families, 
including basic-helix-loop-helix (Myc/Max, PDB 
1NKP), zinc-finger (glucocorticoid receptor, PDB 
1R40), and high mobility group (Lef-1, PDB 
2LEF).55 
 
cascades for precise detection of environmental cues.13 Further, the expanded footprint of 
the bound proteins provides gene specificity. The interferon β (IFNB) gene enhancer is 
an example of the coordinate binding of multiple transcription factors for transcriptional 
activation. The DNA serves as a sequence-encoded scaffold for the binding of ATF-2, c-
Jun, IRF-3A, IRF-7B, IRF-3C, IRF-7D, p50, and RelA at the enhancer of IFNB (Figure 
1.3).13 These factors in turn recruit the coactivators CBP/p300 in a multivalent fashion. 
The composite enhanceosome modifies chromatin and recruits RNA polymerase II to 
transcribe the IFNB gene into messenger RNA. Combining all these elements encoded in 
both the sequence and structure of DNA achieves exquisite control of the transcriptomic 
program.  
Myc/Max Glucocorticoid 
Receptor
Lef-1
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Figure 1.3  Model of the interferon β enhanceosome. 17 
 
 
1.4  Molecular recognition of DNA 
The sequence-specific molecular recognition of DNA is key to this regulatory 
system. DNA is comprised of four nucleotides linked by anti-parallel phosphodiester 
backbones in a double helix (Figure 1.4). In the B-form DNA typically found in nature, 
the four nucleotides hydrogen-bond by the Watson-Crick pairings: adenosine (A) pairs 
with thymine (T) through two hydrogen bond interactions; cytosine (C) pairs with 
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Figure 1.4  Structure of deoxyribose nucleic acid. DNA 
comprised of four nucleic acid bases linked by a 
phophodiester backbone in a double helix (PDB 1BNA) is 
shown.59  
 
guanosine (G) through 3 hydrogen bonding interactions.18 This specific pairing pattern 
provides for heritability of the genetic code as identical daughter genomes are 
synthesized during replication following the base complementarity. The exposed edges of 
the base pair form a wide major groove and a narrow minor groove on opposite sides of 
the double helix (Figure 1.4). Each of the four base pairs exposes a unique stereo- 
electronic edge in the grooves (Figure 1.5A). These sequence-specific stereo-electronics 
are recognized by DNA binding proteins. In addition, they are recognized by small 
molecule ligands which may be used to modulate the binding activity of the proteins.  
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Figure 1.5  Each base pair has a unique stereo-electronic 
edge in both the major and minor groove.55 Hydrogen-
bonding patterns are shown for both the major and minor 
groove for each of the base pairs. Circles with two dots 
represent lone pairs and circles with an H represent a 
hydrogen on the exocyclic amine of guanine.  
 
There are DNA-binding natural products with known sequence specificity that 
have been successfully employed as therapeutic drugs and scientific tools. Actinomycin 
D is a DNA-intercalator with a sequence preference for 5’-GC-3’ that was one of the 
earliest chemotherapeutics for cancer (Figure 1.6).19 Echinomycin is a bis-intercalating 
minor groove binding ligand that preferentially binds 5’-(A/T)CGT-3’ and was found to 
downregulate hypoxia inducible factor transcriptional activity (Figure 1.6).20-22 
Fluorescent DNA-binding ligands such as DAPI have seen wide use as nuclear stains in 
microscopy (Figure 1.6).23,24 Among DNA minor groove-binding ligands, distamycin and 
netropsin lend themselves to rational design and chemical modification due to their 
modular structure (Figure 1.6).25  
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Figure 1.6  Structures of DNA binding small molecule ligands and their preferred binding 
sequences. 
The minor groove surface of DNA presents a binding target for effecting 
modulation of dysfunctional biology in disease states. Distamycin preferentially binds 
AT-tracts, as there is steric hindrance from the exocyclic amine of guanosines in 
C•G/G•C on the minor groove floor (Figure 1.7A).26 The introduction of a N-methyl 
imidazole ring (Im) to replace a N-methyl pyrrole ring (Py) provides a “hole” for the 
“bump” of the guanine residue.27,28  In particular, the 2:1 binding of distamycin in the 
minor groove of DNA29 (Figure 1.7B) suggested that linked Py-Im polyamides can target 
sequences through cofacial arrangement of the aromatic ring pairs to distinguish the 
edges of the four Watson-Crick base pairs.30 Pairing rules for programmable specificity 
have been determined: Im/Py specifies a G•C base pair, Hp/Py codes for T•A base pairs 
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Figure 1.7  Crystal structures of distamycin bound in the 
minor groove of DNA. A) Distamycin bound 1:1 (PDB 
2DND) and B) 2:1 in an antiparallel orientation (PDB 
378D).59  
 
and Py/Py binds both T•A/A•T (Figure 1.8).27,28,31-34 This pairing register of the 
antiparallel polyamide strands can be covalently enforced with a γ-amino butyric acid 
linker to form a hairpin architecture.35 However, Py-Im polyamide strands, particularly 
those containing many imidazoles, were found to be over-curved compared to natural 
DNA.36 β-alanine residues were introduced to relieve the curvature in such cases, which 
allowed targeting longer sequences and sequences with more C•G/G•C residues.37-41 The 
development of this molecular recognition technology has enabled sequence-specific 
targeting of DNA with affinities similar to that of transcription factors.42 
 
Distamycin
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Figure 1.8  Pairing rules for Py-Im polyamide DNA sequence-specificity. A) Hydrogen-
bonding pattern of the minor groove is depicted as described above. Model for the binding 
of a ImHpPyPy-γ-DABA-ImHpPyPy-tri-IPA polyamide bound to 5’-AGTACT-3’. 
Hydrogen bonds shown with dashed lines. B) Ball and stick notation for polyamides, with 
legend in C). 
 
1.5  Biological modulation with Py-Im polyamides 
Studies support Py-Im polyamides effecting biological modulation through its 
DNA binding capacity. The accessibility of DNA in the context of chromatin for Py-Im 
polyamide binding was demonstrated in a crystal structure of a polyamide bound to the 
nucleosome core particle (Figure 1.9A). In live cell culture experiments, the cell-
permeability and nuclear localization of dye-conjugated polyamides were observed  
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Figure 1.9  Py-Im polyamides access chromatin. A) Crystal structure of a nucleosome core 
particle with B) polyamide dimer 1 bound in the adjacent minor grooves.60 C) Confocal 
microscopy of MCF-7 breast cancer cell line treated with nuclear-stain Hoechst or D) dye-
conjugate polyamide 2.61 Images show co-localization to the nucleus.  
 
through confocal microscopy in a wide range of cell lines (Figure 1.9C).43-44 This 
demonstrated that access to chromatin with no external transfection was possible with 
these oligomers. Transcriptional modulation was demonstrated in cell culture by Py-Im 
polyamides targeted to the respective consensus binding sequences of the transcription 
factors hypoxia-inducible factor, androgen receptor, glucocorticoid receptor, and NF-
κB.46-50 An X-ray crystal structure of a cyclic polyamide bound to DNA provided a 
rationale for the exclusion of major-groove binding proteins upon minor groove binding 
by the polyamide.51 The crystal structure revealed that polyamide binding caused an 
expansion of the minor groove and compression of the major groove (Figure 1.10). Py-Im 
polyamides were also found to disrupt processive DNA enzymes. For example, a high  
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Figure 1.10  Allosteric disruption of major groove by minor groove binding cyclic 
polyamide.51 A) Structure of cyclic polyamide 4. B) Ball-and-stick notation for 
polyamide 4 shown with the sequence of the DNA oligonucleotide. C) Crystal structure 
of native B-form DNA (PDB 1D8G). D) Crystal structure of cyclic polyamide 4 bound in 
the minor groove of DNA (PDB 3OMJ). E) Binding of polyamide 4 causes a distortion to 
the native DNA structure. F) The binding of polyamide 4 causes a widening of the minor 
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groove (top), and a compression of the major groove (bottom). Native structure shown in 
yellow, polyamide-bound structure shown in blue. 
 
affinity hairpin targeted to the androgen response element also disrupted RNA 
polymerase II elongation, causing cytotoxicity and p53 activation without DNA 
damage.52 Another study showed that high doses of this polyamide can disrupt helicase 
activity and can cause replicative stress.53 These results indicate DNA minor groove 
binding Py-Im polyamides can cause a variety of alterations to biological activity. 
 
Studies in mouse models have shown that many of these effects observed in cell 
culture translate to the mouse with systemic treatment of the polyamide. 
Pharmacokinetics studies have shown that Py-Im polyamides are bioavailable and have 
reasonable exposure.54 Cyclic architecture and acetylation of the turn of the same core 
aromatic oligomer sequence have each been explored and shown to have different 
pharmacokinetic and toxicity profiles.55,56 Gene expression has been measured in the 
tumor of mouse xenograft models and shown to be modulated by polyamide treatment 
similarly to the experiments done in cell culture.57 In a xenograft model of prostate 
cancer, the high-affinity Py-Im polyamide targeted to the androgen receptor response 
element reduced tumor size.52 Indeed, a C-14 labeled analog of the molecule showed 
preferential localization to the tumor xenograft.58 In sum, Py-Im polyamides are a class of 
molecules well-suited for the study of biological perturbation through DNA binding. 
 
1.6  Scope of Work 
This thesis describes studies of Py-Im polyamides targeted to biologically 
important DNA repeat sequences for the purpose of modulating disease states. In chapter 
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2, a Py-Im polyamide is designed to bind a sequence that contains two CG dyads and is 
tested as a DNA methylation antagonist. Chapter 3 explores the immunogenic signaling 
triggered by a polyamide that is targeted to the telomere repeat sequence. Chapter 4 
describes work in assessing the animal toxicity of hairpin polyamides targeted to the 
CAG/CTG triplet repeat expansion to disrupt the transcription of the associated RNA, 
which is the molecular cause of myotonic dystrophy type 1. Chapter 5 describes a ChIP-
seq experiment that explores the genome-wide perturbation of hypoxia-inducible factor 
occupancy induced under hypoxia by a Py-Im polyamide targeted to the consensus 
sequence of the hypoxia response element. 
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Chapter 2 
 
 
Design of Sequence-Specific DNA Binding Molecules 
for DNA Methyltransferase Inhibition 
 
 
 
 
 
 
 
 
 
The text of this chapter is taken in part from a manuscript co-authored with Jordan L. 
Meier and Peter B. Dervan (California Institute of Technology). 
 
(Kang, J. S.; Meier, J. L.; Dervan, P. B. J. Am. Chem. Soc. 2014, 136, 3687-3694.) 
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Abstract 
The CpG dyad, an important genomic feature in DNA methylation and transcriptional 
regulation, is an attractive target for small molecules.  To assess the utility of minor 
groove binding oligomers for CpG recognition, we screened a small library of hairpin 
pyrrole-imidazole polyamides targeting the sequence 5′-CGCG-3′ and assessed their 
sequence specificity using an unbiased next-generation sequencing assay. Our findings 
indicate that hairpin polyamide of sequence PyImβIm-γ-PyImβIm (1), previously 
identified as a high affinity 5′-CGCG-3′ binder, favors 5′-GCGC-3′ in an unanticipated 
reverse binding orientation. Replacement of one β alanine with Py to afford PyImPyIm-
 γ-PyImβIm (3) restores the preference for 5′-CGCG-3′ binding in a forward orientation. 
The minor groove binding hairpin 3 inhibits DNA methyltransferase activity in the major 
groove at its target site more effectively than 1, providing a molecular basis for design of 
sequence-specific antagonists of CpG methylation. 
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2.1  Introduction 
The role of epigenetic dysregulation in cancer has motivated interest in DNA 
methylation and methods for its modulation.1,2  In mammals, DNA methylation occurs in 
the major groove of DNA at the 5′ position of both cytosine residues in the palindromic 
CG dyad (CpG).  CpG’s are rare in the genome and 70% methylated, with nearly all 
unmethylated CpG’s clustered in G,C-rich regions called “CpG islands”.3  Approximately 
60% of RNA Polymerase II transcribed human genes contain CpG islands,4 and their 
methylation causes transcriptional repression.5  In cancer, for example, otherwise 
functional tumor suppressor genes can be silenced by hypermethylation in their 
associated CpG island.6  Importantly, inhibition of DNA methylation at tumor suppressor 
genes has been shown to reactivate apoptotic pathways and sensitize cancer cells to 
previously ineffective chemotherapy.7,8    
 
The most effective demethylation agents are cytidine analogs such as 5-aza-
deoxycytidine, which find limited use due to significant side effects.1  These cytidine 
analogs are suicide inhibitors incorporated into DNA to form covalent methyltransferase-
DNA adducts.9  The methyltransferase is sequestered and unavailable to methylate 
CpG’s, resulting in genome-wide demethylation. DNA binding molecules, such as the 
bis-intercalating natural product echinomycin,10 can disrupt CpG methylation in vitro but 
have dose-limiting toxicities that have abrogated further clinical advancement.11 While 
other CpG methylation inhibitors are under investigation,12-14 none of these agents have 
demonstrated the ability to inhibit DNA methylation in a sequence-specific fashion. 
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Hairpin pyrrole-imidazole (Py-Im) polyamides are a class of sequence-specific 
oligomers that bind in the minor groove of DNA.15-20 Programmable sequence preference 
is accomplished by side-by-side pairings of aromatic amino acids that distinguish the 
edges of the four Watson-Crick base pairs.15-20  Referred as the pairing rules, Im/Py codes 
for G•C base pairs, Hp/Py codes for T•A base pairs, and Py/Py binds both T•A/A•T in 
preference to G•C/C•G.  Eight-ring hairpin oligomers linked by a central aliphatic γ-
aminobutyric acid unit have affinities for match sites with Ka ~108 to 1010 M-1.16,21  These 
binding energetics are comparable to natural transcription factors, and like natural DNA 
binding proteins, are sensitive to differences in the sequence-dependent microstructure of 
DNA.  To relax the curvature of all ring hairpins, β alanine (β) can be substituted for Py-
rings in some cases such that β/β pairs replace Py/Py for T•A/A•T specificity, and Im/β 
replaces Im/Py pairs in strategic locations while retaining specificity for G•C base pair.22-
26  Hairpin Py-Im polyamides usually bind with the N-to-C terminus aligned in the 5′-to-
3′ direction of DNA, referred to as “forward orientation”.27  This modest forward binding 
preference can be enforced by substitution of the prochiral α position in the γ-turn, i.e., 
replacement of γ-aminobutyric acid by (R)-2,4-diaminobutyric acid.28  Hairpin 
architectures containing β/β pairs and β/ring pairs have been found in some cases to 
prefer the N to C terminus aligned in a 3′-to-5′ direction of DNA.29  While adhering to the 
pairing rules, this reverse hairpin orientation would bind a different DNA sequence.  
Recently we used massively parallel sequencing methods in conjunction with biotin-
tagged hairpins, termed Bind-n-Seq, to scan genome-size DNA sequence space for  
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Figure 2.1  Structure of Py-Im polyamides S1 and S2 previously reported to bind methylated 5’-
CGCG-3’ oligonucleotide duplex.32  Legend for ball-and-stick notation. 
 
hairpin high affinity sites.30 Although the canonical pairing rules are remarkably 
predictive of polyamide DNA binding specificity, we identified high affinity DNA 
binding sites in the reverse orientation for several polyamides containing β/Im pairs.30 
 
Eight-ring hairpin Py-Im polyamides have been shown to discriminate 5′-GGGG-
3′, 5′-GCGC-3′ and 5′-GGCC-3′ with appropriate arrangement of four Im/Py pairs.31  
From experience, sequences with CpG steps such as 5′-CGCG-3′ are not as readily 
accessed for reasons not well understood.  In an effort to improve the affinity of an eight-
ring hairpin polyamide for the sequence 5′-CGCG-3′, Sugiyama and coworkers replaced 
two Im/Py pairs with Im/β pairs (Figure 2.1).  A change from PyImPyIm-γ-PyImPyIm 
(S1) to PyImβIm-γ-PyImβIm (S2) afforded a 65-fold increase in affinity for 5′-CGCG-
3′.32  Both hairpins conform to the pairing rules and would bind 5′-CGCG-3′ in the 
forward orientation. In this study, we employ a high-throughput sequencing assay of 
polyamide-DNA association to revisit targeting the 5′-CGCG-3′ sequence. Our findings 
indicate that hairpin polyamides of sequence PyImβIm-γ-PyImβIm S2 favor 5′-GCGC-3′, 
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a reverse binding mode.  The issue of designing a hairpin polyamide sequence that 
prefers 5′-CGCG-3′ to 5′-GCGC-3′ remains to be solved.  Using Bind-n-Seq methods30 as 
our screen for a library of polyamide-biotin conjugates, we find that replacement of one β 
alanine with Py to afford PyImPyIm-γ-PyImβIm restores the preference for forward 
binding 5′-CGCG-3′.  Recent structural work has shown that a cyclic Py-Im polyamide 
binding in the minor groove causes significant widening of the minor groove width of  
DNA,33,34 and provides a mechanistic rationale for disruption of DNA-binding proteins in 
the major groove.  We demonstrate the ability of our 5′-CGCG-3′ specific minor groove 
binding hairpin polyamides to inhibit enzymatic CpG methylation in the major groove of 
a 5′-CGCG-3′ sequence. 
 
2.2  Results 
Sequence Based Analysis of PyImβIm-γ-PyImβIm Specificity.  The 5′-CGCG-
3′ sequence is a compelling DNA target for an 8-ring hairpin Py-Im polyamide because it 
is one of the least represented 6-bp sequence patterns in the human genome, potentially 
promoting greater genomic specificity.30  Minoshima and coworkers have previously 
targeted this sequence and shown that polyamide S2 (Figure 2.1) can bind the fully 
methylated sequence.32  In their study, the substitution of two β’s for Py moieties resulted 
in improved affinity for 5′-CGCG-3′ over the eight-aromatic ring architecture S1 (Figure 
2.1).  In light of recent Bind-n-Seq studies, however, we wondered whether these changes 
may have also had the unintended effect of reducing the preference of the polyamide for 
binding in the forward orientation.30  Bind-n-Seq is a high-throughput sequencing method  
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Figure 2.2  A) Scheme of Bind-n-Seq method.30  Polyamide-
biotin conjugate is incubated in a genome-sized library of all 
possible 21mers, enriched, sequenced, and the resulting 
dataset analyzed with motif-finding software.30  B) Polyamide 
1 could potentially bind in the forward orientation or the 
reverse orientation.  The highest affinity binding sequence of 
1 is the reverse orientation binding 5’-GCGC-3’. 
 
that allows facile identification of high affinity binding sites of biotin-labeled Py-Im 
polyamides by affinity purification followed by sequencing (Figure 2.2A).30  As a first 
step, we synthesized an analog of S2 and examined polyamide-biotin conjugate 1 of 
sequence PyImβIm-γ-PyImβIm (Figure 2.2B), which has a biotin affinity tag appended at 
the C-terminus of the heterocyclic oligomer (Figure 2.3). Polyamide-biotin conjugate 1 
was incubated at 50 nM in a library of all possible 21 base pair DNA sequences,  
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Figure 2.3  Structures of Py-Im polyamides 1-3. 
 
enriched, and sequenced to identify polyamide-bound sequences. This dataset was then 
analyzed by the DREME algorithm to construct a motif logo summarizing the highest 
affinity sequences.  A binding preference for 5′-GCGC-3′ was revealed, suggestive of a 
reverse binding mode (Table 1).   
 
Redesign Hairpin for CGCG versus GCGC Preference.  In order to restore the 
preference for binding 5′-CGCG-3′ in the forward orientation, we considered two 
possible points of modification (Figure 2.4A).  First, we made a single modification to 1 
at the turn unit, replacing the GABA turn to a chiral γ-amino GABA, affording 2 (Figure 
2.3 and 2.4B). The γ-amino GABA turn has previously been shown to restore forward 
orientation and increase affinity, including in β-containing polyamides.28-30 This effect is 
thought to arise from a steric interaction with the floor of the minor groove when the 
chiral α-amino GABA turn unit is bound in the reverse orientation.23,28 Assessment of 
polyamide 2 by Bind-n-Seq found that this modification improved the reverse/forward 
ratio but was insufficient to restore a forward orientation binding preference (Table 2.1). 
To confirm the high-throughput sequencing findings, we performed a thermal DNA 
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Table 2.1  The preferred binding orientations of polyamides 1-8 were queried with Bind-n-Seq 
to generate the highest affinity sequence motif.  Polyamide-mediated thermal stabilization (ΔTm) 
of 12 base pair oligonucleotides of the forward (5′-CGCG-3′) and reverse 5′-GCGC-3′ sequences 
were use to validate the revealed motifs.  Melting temperatures reflect the mean and standard 
deviation of quadruplicate measurements. 
 
 
 
denaturation study, as previous studies have shown the thermal stabilization (ΔTm) of 
duplex DNA by Py-Im polyamides correlates well with binding affinity.35  Assays were 
performed with DNA oligonucleotides differing only in the central binding sequence (5’- 
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Figure 2.4  A) Scheme of Py-Im polyamide binding in 
the minor groove of DNA. B) Single position changes 
made to hairpin polyamide 1 to afford 2 and 3. Positions 
are highlighted in yellow. 
 
CGCG-3’ versus 5’-GCGC-3’) to directly test the binding orientations identified by the 
Bind-n-Seq logos (Table 2.1).  This analysis substantiated a reverse orientation binding 
preference for polyamide 1, with a ΔTm of 10.9 ºC in the reverse direction as compared to 
3.4 ºC in the forward direction. Modification at the turn to the γ-amino GABA in 
polyamide 2 resulted in increased stabilization of the forward 5′-CGCG-3′ oligomer by 
4.5 ºC; stabilization by polyamide 2 in the reverse 5′-GCGC-3′ orientation was 
diminished by 2.0 ºC.  This indicated an improved forward preference for 5′-CGCG-3′.  
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Nonetheless, the relative magnitudes of the ΔTm support an overall modest energetic 
preference for reverse orientation binding. 
 
The inability of the γ-amino GABA turn to enforce forward orientation binding 
led us to investigate alternative solutions for the molecular recognition of 5′-CGCG-3′.  
We posited that reverse binding is abetted by the flexibility afforded by the two β units in 
the core binding region, as had been similarly noted in polyamides containing a β/β 
pair.29  We thus considered whether removing one β residue might reinstitute sufficient 
rigidity in one of the polyamide strands to limit reverse binding while retaining the 
specificity and affinity provided by the other β.  Of the two β moieties in the core of 
polyamide 1, the C-terminal β in the core binding region was retained based on previous 
studies that have shown it is necessary for high affinity recognition of the 5′ C•G base 
pair.24  To isolate the effect of each modification, we returned to parent polyamide 1 and 
replaced the N-terminal β with a Py while retaining the achiral GABA turn, to provide 
polyamide 3 (Figure 2.3 and 2.4B).  The assessment of 3 by Bind-n-Seq followed by 
DREME analysis generated a high affinity motif consistent with forward binding 5′-
CGCG-3′ (Table 2.1).  This was corroborated by ΔTm measurements showing 
considerable preference for the forward 5′-CGCG-3′ direction.   
 
 We further examined whether a hairpin polyamide designed to target a reverse 
orientation sequence may productively bind CpG’s with high specificity.  To test this, we  
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Figure 2.5  A panel of polyamides was synthesized for 
assessment by Bind-n-Seq and DNA thermal 
stabilization for binding the 5’-CGCG-3’ sequence.  
According to the pairing rules, polyamides 1-4 target 
5’-CGCG-3’ in the forward orientation and 
polyamides 5-8 target 5’-CGCG-3’ in the reverse 
orientation.  Structural modifications are highlighted in 
yellow. 
 
expanded the library of compounds to include polyamides 4-8, which contain single 
modifications targeting the 5′-GCGC/CGCG-3′ core (Figure 2.5 and 2.6).  In contrast to 
our findings with 5′-CGCG-3′ targeting polyamide 2, we confirmed that the incorporation 
of an α-amino GABA turn in polyamide 6 restores forward orientation binding for the 5′-
GCGC-3′ sequence.30  This difference is striking given the two polyamides are composed 
of nearly identical amino acid sequences.  Bind-n-Seq data and Tm assays of polyamides 
4, 5, 7, and 8 together suggest that all other modifications preferentially bind the reverse 
orientation, and 5, 7, and 8 do so with poor specificity (Table 2.1).  Indeed, amongst all 
variations tested of both 5′-CGCG-3′ forward binding and 5′-GCGC-3′ reverse binding 
cores, polyamide 3 displayed the highest specificity for the 5′-CGCG-3′ sequence (Table 
2.1). 
2
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Figure 2.6  Structures of Py-Im polyamides 4-8. 
 
Sequence-Specific Binding Hemi-methylated DNA.  Next, we considered the 
potential for minor groove binding hairpin Py-Im polyamides to prevent DNA 
methylation undergoing DNA replication.  To do so, they must be able to bind the hemi-
methylated DNA of daughter strands that have not yet undergone maintenance 
methylation.  DNA thermal stabilization analysis was used to pursue evidence of the 
above trends of binding orientation with hemi-methylated DNA sequences.  The sense 
strand of each of the 12 base pair oligomers containing 5′-CGCG-3′ or 5′-GCGC-3′ cores 
were methylated on both cytosines, whereas the antisense strand was left unmethylated.  
Flanking sequences were modified to lack self-complementarity and enforce hemi-
methylated duplex formation.  Analysis of ΔTm of the hemi-methylated DNA oligomers 
confirmed the above magnitudes of stabilization and trends of reverse and forward 
binding modes for 1, 2, and 3 (Table 2.2A). 
 
Inhibition of Methyltransferase.  With a specific polyamide capable of binding  
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Table 2.2  A) Tm study with hemi-methylated DNA duplex. B) Tm study of three generations of 
5′-CGCG-3′ methylation inhibitors without biotin affinity tags. 
 
 
 
hemi-methylated DNA in hand, we evaluated its application as a sequence-specific 
inhibitor of DNA methyltransferases.  The biotin enrichment tag was deleted from the C-
terminus by re-synthesis to afford parent hairpins 1b and 3b (Figure 2.7). Melting 
temperature analyses confirmed these molecules show comparable binding preference to 
biotin conjugates 1 and 3, respectively (Table 2.2B).  We developed an in vitro assay to 
probe the methylation state of specific sites employing the methylation-sensitive 
restriction enzyme MluI to compare sequence specific effects of 1b, 3b, and AT-binding 
distamycin D as a control (Figure 2.8A).  In this assay, we measured the ability of these  
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Figure 2.7  Structures of polyamides 1b, 3b, D, and 9b used in in vitro 
functional assays. 
compounds to inhibit the methylation activity of M.SssI, a robust prokaryotic 
methyltransferase that operates in a processive manner like human methyltransferases 
and shares structural similarities with the catalytic core of human DNMT1.36  We 
employed the methylation-sensitive enzyme MluI, which cleaves at seven 5′-ACGCGT-3′ 
sites,37 to interrogate methylation of the lambdaphage DNA (48.5 kb), of which five 
bands were visualized by agarose gel electrophoresis.  Both 1b and 3b were titrated from 
increasing concentrations 1 nM to 1 µM while D was dosed ten-fold higher from 10 nM 
to 10 µM.  Full digestion of the DNA by MluI indicates a lack of CpG methylation at 5′-
ACGCGT-3′ restriction sites, and is demonstrated by positive control lane 2 (Figure 
2.8B).  In contrast, full methylation would protect DNA from MluI digestion, as in lane 1, 
where no compound was added to DNA prior to exposure to M.SssI for methylation. 
 
Consistent with our biophysical characterization of the compounds, polyamide 3b 
showed the most robust inhibition of CpG methylation (Figure 2.8B, lanes 7-10) at  
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Figure 2.8  A) Scheme of in vitro assay of DNA methyltranferase inhibition.  Generic 
polyamide shown in ball-and-stick notation, CpG sites represented by red squares. (B) 
Inhibition of methyltransferase activity reflects sequence-specificity of Py-Im polyamides.  
Lambdaphage DNA was incubated with M.SssI and subject to methylation-sensitive 
restriction digest at 5’-ACGCGT-3’ sites by MluI.  DNA is 240 pM in match sites.  Positive 
control lane 2 was not subject to methylation and completely digested while negative control 
lane 1 shows minimal digestion.  Increasing concentration of 3b inhibits methylation at the 
restriction sites as visualized by additional, smaller restriction fragments.  Polyamide 1b and 
3b was titrated from 1 nM to 1 µM at ten-fold dilutions and distamycin ranged from 10 nM to 
10 µM at ten-fold dilutions.  Visualized on 0.7% agarose gel with SYBR gold. 
 
5′-ACGCGT-3′ sites.  In lane 10, full MluI digestion comparable to positive control lane 
2 was observed at 1 µM of 3b, indicating this concentration was sufficient to block all 
methylation at the cognate binding sites.  Further, incomplete protection was evidenced at  
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100 nM of 3b by additional, partially digested bands in lane 9.  In contrast, polyamide 1b 
showed weak inhibition of M.SssI and was active only at the highest concentration 
(Figure 2.8B, lanes 3-6). This reflects its weaker affinity for the 5′-CGCG-3′ forward 
binding orientation, also observed by thermal duplex denaturation analysis.  Inhibition by 
1b at 1 µM, however, was reduced relative to that observed at 100 nM of 3b, consistent 
with the binding preferences of the two molecules.  There was no inhibition by 
distamycin D at all concentrations tested, even at the highest concentration of 10 µM, 
underscoring the importance of CpG specificity of Py-Im polyamides in preventing CpG 
methylation. To enable quantitation of enzyme activity inhibition, the substrate DNA was 
changed to a 7.5 kb fragment containing a single 5′-ACGCGT-3′ site (Figure 2.9A). 
 
We were encouraged by these results to consider the design of an improved 
methylation antagonist at 5′-CGCG-3′.  We revisited the single modifications to 1 in 
polyamide 2 and 3 that had promoted forward orientation binding.  We combined the γ-
amino modification at the GABA turn that had encouraged 2 to bind in the forward 
orientation, albeit insufficiently, with the Py substitution in the top strand, as in 3, to 
afford 9b (Figure 2.9B).  Analysis by thermal denaturation assays revealed that the 
effects of the modifications were additive, and 9b displayed increased affinity and 
preference for forward orientation binding (Table 2.2B).   
 
We then sought to determine IC50 values for the three generations of 5′-CGCG-3′ 
methylation inhibitors: 1b, 3b, and 9b.  With consideration for their DNA binding  
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Figure 2.9  A) Scheme of in vitro DNMT inhibition assay with single restriction site.  Generic 
polyamide shown in ball-and-stick notation and CpG sites represented by red squares.  DNA (7.5 
kb) with a single MluI restriction site was incubated at 50 pM with inhibitor and subjected to 
methylation by M.SssI.  DNA was isolated for restriction digest by MluI to reveal methylation at 
the target site. B) Single changes in polyamides 2 and 3 that promote forward orientation binding 
were combined in designing 9b as a third generation candidate for improved methylation 
inhibition. C) Representative gel image of the polyamides 1b, 3b, and 9b in the assay described 
in (A), suggestive of differential inhibitory activity. Dose ranges of compounds were adjusted in 
relation to their DNA binding affinities.  D) IC50 values of 5′-CGCG-3′ targeting polyamides.  
Values are determined from band intensities in the in vitro as assay shown in (C) and normalized 
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against maximal methylation with no inhibitor.  IC50 values were calculated from at least three 
replicates and fit to a four-variable, dose-response model.   
 
affinities, compounds 1b, 3b, and 9b were titrated from 10 nM to 33 µM, 330 pM to 10 
µM, and 33 pM to 1 µM, respectively (Figure 2.9C).  It is worth noting that an additional 
SDS wash step was necessary in this assay to remove the higher affinity 9b from the 
DNA before resolution by the MluI restriction enzyme.  Prior to the addition of this SDS 
incubation, inhibition was maximally revealed to approximately 40%, due to polyamide 
inhibition of the MluI restriction enzyme.  Overnight incubation of DNA in 2% SDS 
removed additional polyamide and improved the revealed inhibition, suggesting the 
compressed inhibitory range is an artifact of this method and the high affinity of 9b.  The 
IC50 values of 1b, 3b, and 9b were determined to be 2.2 µM (95% confidence: 1.2-3.9 
µM), 117 nM (95% confidence: 65-210 nM), and 2.6 nM (95% confidence: 1.0-6.7 nM), 
respectively (Figure 2.9D).  This is in good correlation with the iterative improvement 
shown in the biophysical analyses of these compounds, as well as the previous qualitative 
in vitro assay.  Polyamide 9b shows nearly 1000-fold improvement over 1b as a 5′-
CGCG-3′ methylation antagonist.  
 
2.3  Discussion 
Design of Antagonists of CpG Methylation.  This study provides a basis for 
design of sequence-specific DNA-binding molecules for targeted inhibition of CpG 
methylation.  The disparity in methyltransferase inhibition between AT-binding 
distamycin D and hairpin polyamide 3b suggests that the specific CpG-binding capability 
and widening of the minor groove by bound Py-Im polyamides are critical for disrupting 
DNA methylation in the major groove.  At the same time, applying the pairing rules 
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demands caution in the design of imidazole and β-rich polyamides, as the inherent 
conformational flexibility of the β subunit can support unintended reverse DNA-binding 
modes.  While previous studies have shown that an β-amino GABA turn unit can be used 
to restore the forward orientation binding preference of β-containing polyamides, we 
found 5′-CGCG-3′ binding Py-Im polyamides required an alternative solution.  
Specifically, restoring the rigidity of the N-terminal strand via substitution of its β-
subunit with a Py appears necessary to resolve the undesired reverse-binding of these 
architectures.  
 
Potential mechanism for inhibition of CpG methylation.  The lack of inhibition of 
CpG methylation by the reverse binding 1b as compared to 3b at the interrogated 5′-
CGCG-3′ sites suggests inhibition of the precessive M.SssI enzyme is a sequence-
specific, localized event. The M.SssI methyltransferase, like eukaryotic 
methyltransferases, is a “flipase” that swings the target cytosine out of the double helix 
and into its catalytic core.38  All known CpG methyltransferases operate by this 
conserved mode of action.  Structural studies of mouse DNMT1, the relevant mammalian 
methyltransferase for maintenance methylation, show that enzyme residues enter the 
double helix from both the major and minor grooves in an intercalative-manner around 
the target CpG.39  These residues disrupt local base pairing and rotate the substrate 
cytosine around the sugar-phosphate backbone and into the catalytic core of the enzyme.  
A Py-Im polyamide bound to the target DNA site likely acts as a stabilizing clamp in the 
minor groove and prevents the intrusion of these residues. The increased DNA stability 
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disallows the conformational reorganization of the CpG substrate necessary for catalysis 
and results in the inhibition of methyltransferase activity. 
 
Conclusion 
In this study, we examined programmable Py-Im polyamides targeting the 5′-
CGCG-3′ sequence as a model for sequence-specific inhibition of CpG methylation.  The 
unbiased Bind-n-Seq method was critical for revealing unanticipated binding modes of 
the polyamides.  Through deliberate, incremental synthetic modifications, we were able 
to discern structure activity relationships that guided improved design of CpG 
methylation antagonists.  Further work will be necessary to understand whether this 
represents a more general solution for controlling Py-Im polyamide orientation or is 
specific to the 5′-CGCG-3′ sequence.  This study demonstrates that high affinity minor 
groove binding Py-Im polyamides can inhibit major groove CpG methylation by 
methyltransferase in a sequence-specific manner.  It will be the focus of future research 
to assess these molecules as antagonists of CpG methylation in cells and its utility in the 
desilencing of specific genes.  It will be of interest whether the intrinsic rarity of the CpG 
dinucleotide sequence and non-covalent binding of polyamides will reduce off-target 
effects. 
 
2.4  Materials and methods 
Py-Im polyamide synthesis. Polyamides were synthesized by microwave-
assisted, solid-phase synthesis on PAM resin (Peptides International) according to 
previously described protocols.40,41  The polyamides were cleaved from resin with 3,3′- 
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diamino-N-methyldipropylamine and purified by reverse phase HPLC.  For biotin- 
conjugated polyamides, the free amine at the C-terminus was allowed to react with 2 
 
Table 2.3  Mass Spectrometry (MALDI-TOF) for Py-Im polyamides. 
Py-Im Polyamide Formula [Mass+H] Found 
PyImβIm-γ-PyImβImβ-(+)-PEG4-Biotin  
(1)  C73H108N25O17S
+ 1638.8 1638.0 
PyImβIm-(R)α-NH2γ-PyImβImβ-(+)-PEG4-
Biotin  (2) C73H109N26O17S
+ 1653.8 1653.8 
PyImPyIm-γ-PyImβImβ-(+)-PEG4-Biotin  
(3) C76H109N26O17S
+ 1689.8 1689.2 
PyImβIm-(R)β-NH2γ-PyImβImβ-(+)-PEG4-
Biotin  (4) C73H109N26O17S
+ 1653.8 1653.8 
ImβImPy-γ-ImβImPyβ-(+)-PEG4-Biotin  
(5) C73H108N25O17S
+ 1638.8 1639.0 
ImβImPy-(R)α-NH2γ-ImβImPyβ-(+)-PEG4-
Biotin  (6) C73H109N26O17S
+ 1653.8 1653.9 
ImPyImPy-γ-ImβImPyβ-(+)-PEG4-Biotin  
(7) C76H109N26O17S
+ 1689.8 1690.1 
ImβImPy-(R)β-NH2γ-ImβImPyβ-(+)-PEG4-
Biotin  (8) C73H109N26O17S
+ 1653.8 1654.1 
PyImβIm-γ-PyImβImβ-(+)-  (1b) C52H73N22O10+ 1165.6 1165.6 
PyImPyIm-γ-PyImβImβ-(+)-  (3b) C55H74N23O10+ 1216.6 1216.4 
PyImPyIm-(R)α-NH2γ-PyImβImβ-(+)-  (9b) C55H75N24O10+ 1231.6 1231.7 
 
 
equivalents of pre-activated PEG4-biotin NHS ester (Thermo Scientific) and 4 
equivalents of DIEA for 1 hour at 55ºC in DMF.  The product was purified by reverse 
phase HPLC and lyophilized.  Purity and identity of compounds were verified by 
analytical HPLC and matrix-assisted laser desorption/ionization time-of-flight (MALDI-
TOF) mass spectrometry (Table 2.3). 
Bind-n-Seq of polyamide-biotin conjugates. Sequence motif logos of the 
highest affinity DNA binding sites of polyamide-biotin conjugates 1-8 were determined 
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according to previously reported methods.30  Each Py-Im polyamide-biotin conjugate was 
equilibrated at 50 nM concentration for 15 hours with a uniquely barcoded library of all 
possible 21mers.  DNA associated with polyamide-biotin conjugates were affinity 
purified with streptavidin magnetic beads (M-280 Dynabeads) and eluted.  Isolated DNA 
was amplified by touchdown PCR and sequenced at the California Institute of 
Technology Millard and Muriel Jacobs Genetics and Genomics Laboratory on an 
Illumina HiSeq 2000 Genome Analyzer.  The generated dataset was then distributed by 
barcode using scripts in the MERMADE pipeline and a fasta file of a random 25% of 
sequences for each compound submitted for DREME motif analysis.30 
DNA thermal denaturation assay. Unmethylated DNA duplexes and hairpin 
polyamides were mixed to a final concentration of 2 and 3 µM, respectively, for 
polyamides 1-8, 1b, and 3b in 1 ml total volume.  For experiments with hemi-methylated 
oligonucleotides, DNA duplexes and hairpin polyamides were mixed to a final 
concentration of 1 and 1.5 µM, respectively.  An aqueous solution of 10 mM sodium 
cacodylate, 10 mM KCl, 10 mM MgCl2, and 5 mM CaCl2 at pH 7.0 was used as analysis 
buffer.  All oligonucleotides (100µM solutions dissolved in 10 mM Tris-Cl, 0.1 mM 
EDTA, pH 8.0) were purchased from Integrated DNA Technologies.  The assay was 
conducted on a Varian Cary 100 spectrophotometer equipped with a thermo-controlled 
cell holder with a cell path length of 1 cm.  Samples were heated to 90 ºC and cooled to a 
starting temperature of 25 ºC prior to heating at a rate of 0.5 ºC/min to 90 ºC.  
Denaturation profiles were recorded at λ= 260 nm and melting temperatures were defined 
as the maximum of the first derivative of the denaturation profile. Reported data 
represents the average of four measurements.   
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In vitro inhibition of CpG methylation assay. In PCR tubes, serially diluted 
concentrations of polyamides 1b, 3b, and distamycin D control were incubated in 96 µl 
of 10 pM unmethylated lambdaphage DNA (Promega) and 1X NEB2 buffer (New 
England Biolabs) in DEPC-treated water (USB) for 12 hours at 25 ºC.  Two additional 
samples of DNA in buffer without compound were kept for controls.  After incubation, S-
adenosyl methionine (New England Biolabs) and M.SssI (New England Biolabs) or water 
was added to all samples to a final concentration of 320 µM and 0.25 Units, respectively, 
to afford 100 µl of total solution. Samples were then incubated for 3 hours at 37 ºC on a 
Biorad MyCycler thermal cycler and heat inactivated for 15 minutes at 65 ºC.  DNA was 
ethanol precipitated in a centrifuge at 4 ºC for 15 minutes with the addition of 10 µl of 
3M NaOAc, 1 µl of glycogen, and 2.5 volumes of ethanol at -20 ºC.  DNA was washed 
once with 75% aqueous ethanol at -20 ºC and allowed to air dry for 30 minutes.  Samples 
were dissolved in 35 µl of water and 15 µl taken for MluI restriction enzyme digestion.  
Samples were prepared in PCR tubes per manufacturer’s protocol with 1 Unit of MluI per 
sample and incubated at 37 ºC for 1 hour.  Blue loading buffer 6x (New England Biolabs) 
was added to samples and 20 µl added to a 0.7% agarose gel in 0.5x TBE buffer.  DNA 
was visualized with SYBR gold (Invitrogen) and a Typhoon FLA9000 Scanner (GE 
Healthcare). 
Determination of IC50. The in vitro assay was run as described above with 1b, 
3b, and 9b at concentrations titrated at 10-fold and 3-fold intervals ranging from 10 nM 
to 33 µM, 330 pM to 10 µM, and 33 pM to 1 µM, respectively, and DNA at 50 pM. The 
substrate DNA fragment (7.5 kb) was PCR amplified from PTYB21 (New England 
Biolabs) after linearization with BamHI (New England Biolabs).  Primers 5′-
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ACTTTTCGGGGAAATGTGCG-3′ and 5′-TTAGAGGCCCCAAGGGGTTA-3′ (IDT 
DNA) were used for amplification with the Expand Long Template PCR System 
(Roche). The amplicon was isolated with QIAquick PCR Purification Kit (Qiagen), and 
the amplicon size was verified by agarose gel electrophoresis. After the ethanol 
precipitation step, which follows methylation, the DNA pellet was dissolved in 100 µl of 
2% SDS and incubated overnight at 55 ºC to wash off residual polyamide. The high 
affinity of 9b made this additional wash step necessary prior to MluI digestion.  To the 
solution, 10 µl of 2M NaCl followed by 2.5 volumes of ethanol were added to re-
precipitate the DNA.  The pellet was washed twice with cold 75% ethanol before 
submission to MluI digest, as described above.  Digested samples were run on 1% 
agarose gels and visualized with SYBR Gold.  Gels were scanned on a Typhoon FLA 
Scanner (GE Healthcare) and the bands quantitated using ImageQuant Software (GE 
Healthcare).  Percentage inhibition was normalized against maximal methylation in the 
presence of no inhibitor. 
% Inhibition =100% × (1- %  !"#!$  !"#%  !"#$%"&  !"#!$  !"# ) 
IC50 curves and 95% confidence intervals were determined using GraphPad Prism by 
variable-slope, nonlinear regression fit to a dose response model with a bottom constraint 
of 0.  At least three replicates of each concentration were used. 
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Chapter 3 
 
 
 
A sequence-specific DNA binding small molecule triggers 
 the release of immunogenic signals and phagocytosis 
 in a model of B-cell lymphoma 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The text of this chapter is taken in part from a manuscript co-authored with Peter B. 
Dervan (California Institute of Technology). 
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Abstract 
 
Means to cause an immunogenic cell death could lead to significant insight into how 
cancer escapes immune control.  In this study, we screened a library of five Py-Im 
polyamides coding for different DNA sequences in a model of B cell lymphoma for the 
upregulation of surface calreticulin, a pro-phagocytosis signal implicated in immunogenic 
cell death.  We found that hairpin polyamide 1 triggers the release of the Damage-
Associated Molecular Patterns (DAMPs) calreticulin, ATP, and HMGB1 in a slow 
necrotic-type cell death. Consistent with this signaling, we observed an increase in the 
rate of phagocytosis by macrophages after the cancer cells were exposed to polyamide 1.  
The DNA sequence preference of polyamide 1 is 5’-WGGGTW-3’ (where W=A/T), 
indicated by the pairing rules and confirmed by the Bind-n-Seq method. The close 
correspondence of this sequence with the telomere-repeat sequence suggests a potential 
mechanism of action through ligand binding at the telomere.  This study reveals a 
chemical means to trigger an inflammatory necrotic cell death in cancer cells. 
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3.1  Introduction 
Avoidance of immune destruction has been called the seventh hallmark of 
cancer.1,2 According to the immuno-editing paradigm, the immune system recognizes and 
destroys those proto-oncogenic lesions capable of triggering an immune response while 
those that escape immune control grow to become clinically detectable disease.3-6 Studies 
suggest that therapies that enlist the immune system maintain more durable disease 
control in the clinical setting.7 Chemical methods to cause immunogenicity in cancer 
cells would be an important tool towards understanding immunomodulation in the 
treatment of cancer. A prerequisite for the activation of an anti-cancer immune response 
is the recognition of the damaged cells as a threat. Damaged cells release 
immunostimulatory molecules, called Damage-Associated Molecular Patterns (DAMPs), 
to recruit and activate professional phagocytes such as macrophages and dendritic cells.8-
10 These antigen-presenting cells engulf and process the cancer cells to further prime the 
immune system for targeted elimination of cancer.11 
 
While most chemotherapeutic regimens cause a non-immunogenic or even 
tolerogenic cell death, recent reports suggest anthracyclins or γ-radiation are particularly 
effective because they result in the release of DAMPs.9,12  The extracellular exposure of 
the intracellularly abundant molecules calreticulin (CRT), HMGB1, and ATP have been 
suggested to form a spatiotemporal code for immunogenicity.13,14 The presentation of 
CRT, an abundant ER-resident chaperone protein, to the cell surface was identified as a 
necessary and sufficient pro-phagocytic signal for professional phagocytes.9 The study  
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Figure 3.1  Py-Im polyamide recognition of DNA minor 
groove and corresponding ball-and-stick notation. 
 
showed that stimulation of CRT surface expression by anthracyclins or adsorbtion of the 
calreticulin protein on the cell surface was sufficient to elicit an anti-cancer immune 
response in syngeneic mice.9 Weissman and coworkers further demonstrated in the Raji 
cell line, a model of human B cell non-Hodgkin’s lymphoma, that CRT is the dominant 
pro-phagocytosis signal that is necessary for engulfment by human macrophages. 15 
Furthermore, ATP released from the cytosol into the local microenvironment serves as a 
lymphocyte recruiting and activating chemokine.16,17 Lastly, the nucleus-resident protein 
HMGB1 can be secreted into the surroundings as an inflammatory adjuvant and was 
shown to be necessary for a durable anti-cancer response in mice.18,19 Identification of 
additional small molecules that trigger the release of these DAMPs from tumor cells 
would be of utility to the field in addressing the heterogeneity of cancers. We became 
interested in expanding the examined chemical space for compounds capable of causing 
an immunogenic cell death. Because the DNA damage pathway has been implicated in 
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immunogenic signaling20 and anthracyclins are DNA-intercalating ligands, we sought to 
explore a class of minor groove DNA-binding oligomers hitherto not studied for this 
biological activity. 
 
 Hairpin pyrrole-imidazole (Py-Im) polyamides are a class of sequence-
specific oligomers that bind in the minor groove of DNA.21-26 Sequence preference is 
achieved by the pair-wise, co-facial arrangement of aromatic amino acids that distinguish 
the edges of the four Watson-Crick base pairs (Figure 3.1A).27 Pairing rules for 
programmable specificity have been established: Im/Py specifies a G•C base pair, Hp/Py 
codes for T•A base pairs, and Py/Py binds both T•A/A•T. 24 Eight-ring hairpin 
polyamides are linked in an antiparallel fashion by a central aliphatic γ-aminobutyric acid 
unit.28 Polyamides of this hairpin architecture have affinities for match sites similar in 
magnitude to natural DNA binding proteins (Ka = 108 to 1010 M-1).29 Eight-ring hairpins 
of this class are cell-permeable and modulate transcription in both cells and mice.30-33 In 
this study, we screened a small library of Py-Im polyamides coding for different six base 
pair DNA sequences in Raji cells for the upregulation of surface calreticulin.  We found 
one hairpin polyamide which displayed activity in this screen and characterize its 
potential for causing an immunogenic cell death. 
 
3.2  Results 
Polyamide 1 upregulates calreticulin on the cell surface. 
We tested five Py-Im polyamides (1-5, Figure 3.2) that bind five unique DNA  
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Figure 3.2  A) Structures of hairpin Py-Im polyamides 1-5 screened for stimulation of surface 
calreticulin (CRT) in Raji cells. B) Structure of ImImIm trimer polyamide 6. 
 
sequences (5’-WGGGWW-3’, 5’-WGWWCW-3’, 5’-WGGWCW-3’, 5’-WTWCGW-3’, 
and 5’-WCGCGW-3’, respectively, where W=A/T) and have demonstrated biological 
activity.30,31,34-36 Raji cells, which have previously been utilized in CRT, phagocytosis, 
and immunotherapy animal models, were dosed at 5 µM for 24 hours with each of the 
polyamides 1-5.  In addition, 5 µM doxorubicin (Dox) and mitoxantrone (Mtx, 1 µM) 
were included as representative anthracyclins. The topoisomerase inhibitor etoposide 
(Eto, 30 µM) was also included for comparison. A 4 hour exposure time point was used 
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Figure 3.3  A) Surface expression of calreticulin measured by flow cytometry, median 
fluorescence normalized to non-treated control (NT). Cytotoxic controls doxorubicin (Dox, 5 
µM), mitoxantrone (Mtx, 1 µM), and etoposide (Eto, 30 µM). B) Dose-dependence of cell 
surface CRT to polyamide 1 was measured by flow cytometry after 24 h treatment.  Measurement 
and standard deviation is in triplicate and representative of two independent experiments; asterisk 
indicates p<0.05 by two-tailed Student’s t-test compared to NT. 
 
to measure CRT due to the high toxicity of these chemotherapeutics and to be in the 
range of literature precedent.9 We measured surface CRT by flow cytometry in a 
population gated for live cells and saw a statistically significant, two-fold increase in cells 
treated with only polyamide 1 (Figure 3.3A). In contrast, we saw no activity with the 
other polyamides 2-5 despite their structural similarity. Notably, polyamide 2 has been 
the most extensively studied amongst this class and has shown activity in prostate cancer 
xenograft models and the DNA damage response.33,37 Remarkably, polyamides 3 and 1 
share the same molar weight and composition of Im/Py pairs, and only differ by the 
exchange of one Im/Py ring pair. To assess the structure activity relationship of the 
imidazole trimer portion of the hairpin oligomer 1, we synthesized and examined 
ImImIm polyamide 6. This was tested because imidazoles are known to complex with 
calcium and CRT is involved in calcium homeostasis.38 We did not, however, observe an 
increase of CRT with polyamide 6, which suggests the imidazole trimer alone is not 
sufficient to trigger the surface expression of CRT. We observed no increase in CRT with 
the two anthracyclins tested, Dox and Mtx, or with Eto. The diminished response to 
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anthracyclin treatment in Raji cells, as compared to that reported in the literature with 
murine colon cancer cells, reflects a known range of CRT response to anthracyclins and 
may be attributable to a difference in cell lines.39,40 We next increased the treatment 
concentration of 1 to 25 and 50 µM and found that CRT exposure increased in a dose-
dependent manner (Figure 3.3B). The results indicate polyamide 1 is unique in our small 
library of compounds in its modulation of surface expression of CRT. 
  
Polyamide 1 preferentially binds the sequence 5’-WGGGTW-3’ 
Py-Im polyamides are a class of sequence-specific DNA-binding ligands and the 
DNA binding preferences of polyamide 1 may be related to a mechanism of action. By 
the pairing rules, polyamide 1 is a perfect match to 5’-WGGGWW-3’, not unlike the 
TTAGGG-repeat sequence found in human telomeres.  Indeed, dye-conjugated tandem 
hairpin Py-Im polyamides that recognize 10 base pairs of this repeat sequence can be 
used to stain telomeres in permeabilized cells.41,42  We sought to confirm the preferred 
binding sequence motif of 1 using the Bind-n-Seq method. Bind-n-Seq couples affinity 
enrichment with next-generation sequencing to query genome-sized sequence space for 
high-affinity binding sequences.43  We modified polyamide 1 at the C-terminal position 
with a biotin-label to afford 1b (Figure 3.4A) for submission to Bind-n-Seq. Polyamide 
1b strongly preferred binding the DNA sequence motif of 5’-WGGGTW-3’ (Figure 
3.4B).  We additionally confirmed the affinity of polyamide 1 for this sequence by 
measuring the thermal stabilization afforded to sequence-matched double-stranded 
DNA.44 We tested a DNA fragment that included the telomeric DNA sequence  
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Figure 3.4  Preferred DNA binding sequence of polyamide 1. A) Structure of polyamide 1b, the 
biotinylated analog of 1. B) Polyamide 1b was tested by the Bind-n-Seq assay and found to 
preferentially bind the described DNA sequence motif. C) Affinity of 1 was assessed by a DNA 
thermal stabilization assay against dsDNA containing the telomeric-repeat sequence 5’-
TTAGGG-3’. D) Immunoblot of γ-H2AX and actin control after the indicated treatment. 
 
 
5’-TTAGGGTTAG-3’ (Figure 3.4C). Polyamide 1 stabilized the 12 base pair DNA 
fragment by 11.5 ºC, suggesting a high affinity hairpin polyamide. Lastly, we detected a 
marker of DNA stress, phosphorylation of serine 139 on the histone H2AX, after 
treatment with polyamide 1 but not 2 (Figure 3.4D).  We chose the 25 µM dose for this 
experiment and others described below because it resulted in a robust six-fold increase in 
surface CRT. We posit that the CRT effect may be due to the unique properties of the 
DNA target sequence of polyamide 1 in cell biology. The DNA stress, thermal 
denaturation, and Bind-n-Seq results together suggest the telomere sequence is a 
plausible target for the mechanism of action of polyamide 1-mediated CRT exposure. 
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Figure 3.5  Treatment of Raji cells with polyamide 1 triggers anterograde CRT 
transport by a different mechanism than previously reported for anthracyclins. A) 
Surface CRT was measured by flow cytometry after Raji cells were treated with 25 
µM polyamide 1 for 12 or 24 h and Brefeldin A (B) for the final 12 h. B) Co-
chaperone ERp57 was measured on the cell surface by flow cytometry after 24 h 
treatment with 1 at 25 µM. C) Caspase inhibitor Z-VAD-fmk (Z, 10 µM) and 
polyamide 1 (25 µM) were dosed together for 24 h and assessed by flow cytometry 
for surface CRT. D) Immunoblots for PARP cleavage and actin control after the 
indicated treatments are shown. All flow cytometry analyses were done in triplicate 
and are representative of at least two independent experiments. Error bars show 
standard deviations and asterisks mark statistically significant changes (p<0.05) by 
two-tailed Student’s t-test compared to no treatment (unless another comparator is 
marked). 
 
Polyamide 1 triggers CRT in a different manner than do anthracyclins  
To better understand the effects of polyamide 1, we compared its trigger of CRT 
to reports of CRT induction by anthracyclins.45 Anthracyclin-induced CRT exposure has 
been described to occur with the co-chaperone ERp57 by anterograde ER-Golgi 
transport.45 To interrogate whether polyamide 1 induces CRT export to the cell surface by 
ER-Golgi transport, we applied the Golgi transport inhibitor Brefeldin A46 (B) to Raji 
cells (Figure 3.5A). Due to the toxicity of B, we could only dose B for 12 hours. With 24 
hour treatment with polyamide 1 and 12 hour treatment with B, we saw statistically 
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significant reduction of CRT on the cell surface when compared to polyamide 1 treatment 
alone (Figure 3.5A). When polyamide 1 and B were dosed together for 12 hours, we saw 
near ablation of all polyamide 1-induced CRT, demonstrating the necessity of this 
pathway for transport.  This further suggests CRT has a half-life on the cell surface of at 
least 12 hours. We additionally measured co-chaperone ERp57 by flow cytometry and 
found that after treatment with 1 for 24 hours, ERp57 increased on the cell surface to a 
similar extent as did CRT, approximately six-fold (Figure 3.5B). These results are 
consistent with previous reports that the translocation of these ER-resident chaperones to 
the plasma membrane occurs by anterograde ER-Golgi transport. 45  
 
Anthracyclin-induced CRT has previously been reported to be mediated by a 
caspase 8- and caspase 3/7-dependent pathway that can be disrupted with the pan-caspase 
inhibitor Z-VAD-fmk (Z).45 Upon co-dosing polyamide 1 with Z, however, we saw no 
decrease in CRT exposure (Figure 3.5C). This caspase-independence was unexpected in 
light of literature precedent as well as the cytotoxicity we observed of 1 during flow 
cytometry experiments. We confirmed the lack of PARP cleavage, a caspase substrate 
cleaved during apoptosis, by immunoblot (Figure 3.5D). We then directly measured 
caspase activity with a luciferase assay after treatment with hairpin polyamides 1 and 2 as 
well as Eto and Dox. We measured a slight increase, approximately 1.2-fold, upon 
treatment with 1 for 24 hours and no increase after treatment with 2. In contrast, we 
measured significant increases of approximately 15-fold each after treatment with Eto 
and Dox (Figure 3.6A). The lack of caspase-dependence and caspase activation would 
suggest the trigger of CRT by 1 is different from anthracyclin DNA intercalators. 
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Figure 3.6  Raji cells undergo a slow, necrotic type cell death after treatment with polyamide 1. 
A) Caspase 3/7 activity was assessed by a luciferase assay after the indicated treatment. 
Measurement is representative of two independent experiments and error bars show standard 
deviations of triplicate measurement. B) Cellular metabolism as a proxy for cytotoxicity was 
measured with a WST-1 assay. Cytotoxic controls etoposide (Eto, 30 µM) and doxorubicin 
(Dox, 5 µM) were included. Measurements were normalized to non-treatment. Graph is 
representative of two independent experiments and error bars represent standard deviations of 
technical quadruplicate. C) Flow cytometry assessment of Raji cells treated with the indicated 
compounds for 24 hours and stained for plasma membrane permeability (7-AAD) and 
phosphatidylserine exposure (Annexin V). Live: lower left; Early necrotic: upper left; Secondary 
necrotic: upper right; Apoptotic: lower right. Representative plots shown of triplicate 
measurement from two independent experiments. D) Assessment as in (B) after 12, 24, and 48 
hour exposure to polyamide 1 at 25 µM. Error bars represent standard deviation of triplicate 
measurement of two independent experiments. 
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Polyamide 1 induces a slow necrotic-type cell death 
We measured cytotoxicity via the metabolic rate with the WST-1 reagent in a 
colorimetric assay. We were surprised to find that treatment with 1, at both 24 and 48 
hours, had little effect on the bioreduction of WST-1 to the formazan dye, suggesting no 
diminution of metabolic rate (Figure 3.6B). This is in stark contrast to the cytotoxic Eto 
and Dox, which showed drastic reduction in cellular metabolism consistent with the 
apoptotic program.  This led us to assess whether polyamide 1 may direct the Raji cells 
towards programmed necrosis. Necrosis is an immunogenic, inflammatory type of cell 
death that is usually attributed to harsh physical insult such as freeze-thaw cycles. 
Recently, a biologically-controlled necrosis program has been described where cells 
undergo early plasma membrane permeabilization with active inflammatory signaling 
and an oxidative burst.47 We compared the mode of cell death after 24 hour treatment 
with hairpins 1 and 2, or Eto by flow cytometry. We analyzed plasma membrane 
permeability and phosphatidylserine exposure on the cell surface to determine 
subpopulations of live, necrotic, and apoptotic cells after compound exposure. Plasma 
membrane permeability was assessed through 7-AAD dye exclusion and 
phosphatidylserine was visualized by dye-conjugated annexin V binding. We found that 
the non-treated control and treatment with hairpin 2 at 24 hours resulted in little cell 
death, but treatment with 1 or Eto caused significant cell death (Figure 3.6C). 
Remarkably, there was a distinct and substantial population of cells treated with 1 that 
lost plasma membrane integrity without phosphatidylserine exposure, indicative of a  
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Figure 3.7  Immunogenic signaling is triggered by polyamide 1 treatment. A) CRT was 
measured by flow cytometry after 24 and 48 h treatment with 1 or 2 at 25 µM. B) Extracellular 
ATP was measured by a bioluminescence assay after the same treatment. C) HMGB1 in the 
supernatant was measured by ELISA after treatment with 1 or 2 at 25 µM. CRT flow cytometry 
and HMGB1 ELISA were measured in triplicate from at least two independent experiments. 
ATP was measured in quadruplicate in three independent experiments. Error bars are standard 
deviations and statistically significant increases (two tailed Student’s t-test, p<0.05) compared 
to non-treatment are indicated by an asterisk.  
 
necrotic cell death. We observed a continuous population from the upper left to the upper 
right quadrant in cells treated with polyamide 1, suggestive of progressive 
phosphatidylserine exposure in permeabilized cells. The upper right quadrant in all 
treatment conditions is secondary necrosis, as there are no phagocytes to remove 
apoptotic or necrotic bodies. There are nearly no cells in the etoposide-treated condition 
that lie in the upper left quadrant, reflective of a canonical apoptotic cell death with intact 
membranes displaying phosphatidylserine. The anthracyclins could not be used in this 
assay due to their inherent fluorescence. We further did a time course of the necrotic 
effect of polyamide 1 at 12, 24, and 48 hours and found that the cells began 
permeabilization as early as 12 hours, and underwent further necrosis by 48 hours (Figure 
3.6D). These assays together suggest polyamide 1 preferentially tracks Raji cells towards 
a slow, necrotic-type cell death even though the cells are capable of apoptosis. 
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Polyamide 1 triggers the release of DAMPs 
The inflammatory nature of necrotic cell death can be attributed in part to the 
release of immune-activating DAMPs.47,48 We measured levels of CRT, ATP, and 
HMGB1 after polyamide 1 treatment, as these DAMPs have been described as key 
factors in a spatiotemporal code of immunogenicity.13,14 We included polyamide 2 as an 
in-class control because 2 has been extensively studied in other cancer models.33 We 
measured CRT by flow cytometry after 24 and 48 hours of compound exposure at 25 µM 
and observed a decreasing trend for surface CRT (Figure 3.7A), consistent with reports 
that CRT is an early response signal.14 Even at the 25 µM concentration of polyamide 2, 
we detected no increase of CRT after 24 hour treatment.  Extracellullar ATP was 
measured with a bioluminescence assay of the supernatant after the same treatment 
regime (Figure 3.7B). The ATP detected in the media after treatment with hairpin 1 was 
greatly increased over the non-treated condition.  We next analyzed the release of 
HMGB1 by running a sandwich ELISA for HMGB1 in the supernatant. After treatment 
for 24 or 48 hours with 1, a significant increase in excreted HMGB1 was detected in the 
media (Figure 3.7C).  The polyamide 1-mediated release of CRT, ATP, and HMGB1 in 
this temporal pattern is consistent with immunogenic signaling described in the literature.  
 
Polyamide 1 treated Raji cells are subject to phagocytosis 
Necrotic cell death with an abundance of externalized CRT and other released 
immunogenic DAMPs should increase phagocytosis. We obtained human peripheral 
blood macrophages and incubated them for 2.5 hours with Raji cells treated with 1 or 2 at  
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Figure 3.8  Treatment of cells with 1 increases phagocytosis by human macrophages.  
A) Schematic diagram of fluorescence-revealed phagocytosis using the pH-sensitive pHrodo 
dye. B) Raji cells treated with the indicated compound at 25 µM for 24 or 48 hours were 
incubated with human macrophages for 2.5 hours. Fluorescein+ cells were assessed by flow 
cytometry for double-positive cells to determine % phagocytosis. C) Raji cells were treated 
with a lower dose of 5 µM of 1 for 24 and 48 hours and assessed for phagocytosis by 
macrophages in the same manner as in (B). D) Fluorescent images of cells prepared as in B) 
are shown. Human macrophages are marked green, free Raji cells are grey in the brightfield 
composite image, and magenta-colored bodies inside macrophages are phagocytosed Raji 
cells. Yellow box in top row is magnified in bottom row images. E) The cell lines A549, 
K562, and PC3 were treated with polyamide 1 for 24 hours and screened by flow cytometry 
for surface CRT. Measurements were in technical triplicate. F) A549 lung carcinoma cells 
treated with 1 for 24 hours was subjected to human macrophages as described above. Graphs 
show mean and standard deviation from three independent experiments for (B), (C), (E), and 
(F). Asterisks indicate statistically significant increases (Student’s two tailed t-test, p<0.05) 
compared to the non-treated condition. Images in (d) are representative of two independent 
experiments. 
 
25 µM for 24 or 48 hours.  The Raji cells’ plasma membrane was covalently decorated 
with a pH-sensitive dye (pHrodo) that is activated when engulfed. Macrophages were 
marked with a cell-permeable fluorescein dye (Figure 3.8A). Macrophages that 
phagocytosed Raji cells are double positive for fluorescein and activated pHrodo dye. In 
each experiment, 1000 macrophages were analyzed by flow cytometry per condition. 
Compared to non-treatment, we found that a greater percentage of macrophages 
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incubated with polyamide 1-treated Raji cells were double positive, and more so at 48 
than 24 hours (Figure 3.8B). We saw little change when macrophages were incubated 
with cells treated with 2. This indicates macrophages phagocytosed Raji cells more 
efficiently after treatment with polyamide 1.  We also tested the lower concentration of 5 
µM of 1 used in the library screening assay, anticipating that immunogenicity may be a 
threshold effect and that 5 µM may be a more reasonable in vivo concentration. We found 
that the treatment of Raji cells with this lower concentration still increased the percentage 
of phagocytosis by macrophages (Figure 3.8C). We then verified the phagocytosis assay 
results with confocal microscopy to ensure that Raji cells were indeed phagocytosed 
rather than externally adherent (Figure 3.8D). The images show that a fraction of 
macrophages have internalized Raji cells, which fluoresce with the activated pHrodo dye. 
The brightfield composite image shows free Raji cells in grey, which are not engulfed by 
macrophages and lack a robust pHrodo signal. The bottom row shows a magnification of 
a macrophage after phagocytosis of a large Raji cell body. 
 
Polyamide 1 triggers CRT and phagocytosis in other cancer cell lines 
We next explored whether this effect might be specific to the Raji B cell 
lymphoma model or more general in other cancer cell lines. We screened the A549 lung 
adenocarcinoma cell line, K562 B cell leukemia cell line, and the PC3 prostate cancer 
cell line for CRT translocation after treatment with 1.  We observed approximately four-
fold increase in CRT surface expression in the A549 and PC3 cell lines (Figure 3.8E). 
Surprisingly, we did not observe an increase in the K562 B cell leukemia cell line (Figure 
3.8E) though they are closest in lineage with the Raji B cells. We then tested the A549 
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cell line in the phagocytosis assay after 24 hour treatment with 25 µM polyamide 1. Even 
though the adherent A549 cell line presents a more difficult target for macrophages, as 
compared to non-adherent Raji cells, we measured an observable increase in A549 
phagocytosis after treatment with polyamide 1 (Figure 3.8F). These results show the 
effects of polyamide 1 extend beyond the Raji cell line to cells of different lineages but 
are not completely general.   
 
RNA-seq of Raji cells after treatment with polyamide 1 or 2 
 To better understand these effects in Raji cells, we examined the change in global 
gene expression after treatment with the polyamides for 24 hours. We isolated RNA from 
Raji cells treated with either polyamide 1 or 2, or untreated and sequenced the 
transcriptome by next-generation sequencing.49 The sequenced reads were mapped by 
Bowtie and Tophat to the Ensembl genes of human genome build 19.50,51 The non-
treated, polyamide 1-treated, and polyamide 2-treated samples were done in biological 
triplicate. The nine total datasets were input into the Cuffdiff algorithm, which identifies 
differentially expressed genes between datasets, accounting for replicates.52 
 In the polyamide 1-treated samples, a total of 576 differentially regulated 
Ensembl genes were identified, of which 528 mapped to unique HGNC genes due to the 
inclusion of haplotypes in Ensembl. Of these, 236 genes were measured to be 
significantly upregulated, of which 154 were upregulated by 25% or greater from the 
non-treated condition (Table 3.1). There were 292 unique HGNC genes downregulated 
by polyamide 1, where 64 were changed by more 25% or greater (Table 3.1). A smaller 
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Table 3.1  Summary of significant, differentially regulated genes from Cuffdiff 
analysis of RNA-Seq data. 
 
  Ensembl 
Unique 
HGNC Gene 
Unique 25% 
change 
Polyamide 1 Upregulated 278 236 154 
 Downregulated 298 292 64 
Polyamide 2 Upregulated 122 121 21 
 Downregulated 118 118 47 
 
 
set of genes were changed by polyamide 2 treatment, with 240 total Ensembl gene 
expression changes found significant, which mapped to 239 unique HGNC genes (Table 
3.1). Of these, 121 genes were upregulated, of which 21 were upregulated by 25% or 
greater. Of 118 genes downregulated by polyamide 2, 47 were downregulated by 25% or 
greater (Table 3.1). A full list of genes up- or down- regulated by 25% or greater upon 
polyamide 1 or 2 treatment is in Tables 3.2-3.5 at the end of the chapter. 
 There were several genes of note upregulated upon treatment with polyamide 1. 
The gene for tumor necrosis factor (TNF), a major cytokine that regulates inflammation, 
was upregulated two-fold (Table 3.2).53 Additionally, the genes HLA-DMA, HLA-DMB, 
HLA-DRB, and HLA-DQB, which encode the major histocompatibility complex (MHC) 
class II and accessory factors, were found to be increased ~40-50% (Table 3.2). HLA-E, 
which codes a non-classical MHC class I molecule that is a ligand for a natural killer cell 
receptor, was also found to be increased over 40%.54 The MHC molecules are critical 
components of antigen recognition in the immune system as they present peptides to T 
cells in the context of a molecular structure unique to the individual.55,56 The upregulation  
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Figure 3.9  Scheme of RNA-Seq 
analysis pipeline. 
 
of these genes is consistent with the inflammatory signaling observed in the previous 
assays. The intermediate early genes EGR1, EGR2, EGR4, and FOS are strongly 
upregulated as well, but given the wide scope of their effects in development,  
differentiation, and cell death, their role in this case is less clear.57-59 These genes are 
markedly absent from the list of genes modulated by polyamide 2, suggesting that this is 
not a class effect, but unique to hairpin polyamide 1. 
 
Genes found to significantly differ from the non-treated condition were then 
submitted for analysis by a cloud-based program created by the Library of Integrated 
Network-based Cellular Signatures (LINCS) to compare gene signatures with those in its  
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Figure 3.10  Structures of compounds identified by LINCS to have 
gene expression profiles similar to A) polyamide 1 and B) polyamide 2. 
 
database of human cells treated with chemical or genetic agents (Figure 3.9).60 The 
structures of the top chemical hits in the LINCS analysis for polyamide 1, shown in 
Figure 3.10A, are not well studied compounds and were not very informative. In contrast, 
several cytotoxic DNA binding molecules were identified for polyamide 2, including the 
topoisomerase inhibitor irinotecan and its active metabolite SN-38 (Figure 3.10B). This is  
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in agreement with previous analyses of polyamide 2 in the LREX and VCaP prostate 
cancer cell lines (Yang, Nickols, Dervan; unpublished) and highlights the differences in 
biological activity between these two molecules.  
 
The LINCS algorithm also compares the up- and down- regulated gene expression 
profile with experiments where single genes were overexpressed. The top 
“overexpression” signatures identified by LINCS included genes that encode MAP2K6, 
GADD45A, TIRAP, and interferon-β. MAP2K6 is a TNF-responsive kinase of p38 
MAPK that integrates stress signals and cytokine signaling.61 GADD45A is a member of 
a family of stress sensors that is responsive to genotoxic stress and affects cell cycling, 
DNA repair, and cell death.62 TIRAP is a signal transducing molecule for the TLR2 and 
TLR4 receptors, which activate the innate immune response.63 Interferon-β is a cytokine 
often produced in response to viral infection that primes adaptive immunity.64 These 
expression signatures include aspects of immune activation and cellular or genotoxic 
stress signaling and may provide leads towards understanding the mechanism of 
polyamide 1 activity.  
 
3.3  Discussion 
In this study, we have discovered a Py-Im polyamide capable of triggering the 
release of immunogenic signals in a necrotic-type cell death. Treatment with polyamide 1 
increased the externalization of CRT, HMGB1, and ATP, which have been characterized 
to be key signals of immunogenicity. We further observed that polyamide 1 causes 
permeabilization of the plasma membrane in a subpopulation of treated Raji cells, which 
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grows from 12 to 48 hours. This occurs even as the apoptotic cell death pathway remains 
competent, as demonstrated by the distribution profile observed after Eto treatment of 
Raji cells. We conclude that polyamide 1 preferentially triggers a necrotic-type, likely 
highly immunogenic cell death, an effect we are not aware has precedent with a small 
molecule synthetic ligand. 
 
Phagocytosis by antigen-presenting cells is a critical step in a chain of events 
towards leveraging the specificity and power of the immune system towards attacking the 
offending target. We saw increased phagocytosis of polyamide 1- treated cells by 
macrophages, as would be expected upon the death of Raji cells with externalized pro-
phagocytic CRT. The observed phagocytosis and inflammatory DAMPs released into the 
tumor microenvironment makes plausible that the immune system would become primed 
towards antigens of Raji cells. Reports have shown engulfment by macrophages can 
activate an effective anti-cancer T cell response.11 The application of polyamide 1 on 
cancer in the context of a full immune system remains to be explored.  
 
That the DNA sequence preference of 1 is identical with that of human telomeres 
was indicated by the pairing rules and confirmed by Bind-n-Seq. Whether the mechanism 
of action for polyamide 1 is through its sequence-specific DNA binding capacity remains 
an open question. Though polyamides have generally been characterized to act in a DNA-
binding mode, we cannot exclude that polyamide 1 may act as an aptamer binding to 
unknown target proteins. The translocation of CRT after polyamide 1 treatment was 
observed in multiple, though not all, cell lines and suggests there is a conserved pathway 
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that leads to this phenotype that is retained in many cancer cell lines. The RNA-Seq 
analysis showed that polyamide 1 triggered the expression of immune activating 
molecules. LINCS analysis of the transcriptomic data suggests similarity to several stress 
response and immune activating gene patterns. We expect the elucidation of the 
mechanism of action will reveal important signaling networks involved in 
immunosurveillance of cancer cells. 
 
Conclusion 
The effects of polyamide 1 are compelling because immunogenic cancer cell 
death is cleared in the natural setting and thus difficult to observe.  Further study may 
reveal tumor suppressive signaling pathways that can be exploited to extrinsically control 
cancer even as cell-intrinsic mechanisms fail.  The failure of anthracyclins to elicit CRT 
in Raji cells when they have previously been shown to be effective in CT26 murine colon 
cancer cells 9 underscores the heterogeneity of cancers.  As cancers have heterogeneous 
mechanisms for evading elimination by the immune system, a corresponding diversity of 
immunogenicity agents will be important for both shedding light on new biology and 
developing immuno-oncologic therapies. 
 
3.4  Materials and methods 
Chemicals and Reagents. All chemicals were purchased from Sigma-Adlrich 
unless otherwise noted. Py-Im polyamides were synthesized by microwave-assisted, 
solid-phase synthesis on Kaiser oxime resin (Novabiochem) according to previously  
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Table 3.6. Mass spectrometry (MALDI-TOF) for Py-Im polyamides. 
 
Polyamide Molecular formula [Mass + H] 
Found 
Mass 
ImImImPy-(R)α-NH2γ-PyPyPyPy-(+)-
IPA (1) C64H76N23O12
+ 1358.6 1358.5 
ImPyPyPy-(R)α-NH2γ-ImPyPyPy-(+)-
IPA (2) C65H77N22O12
+ 1357.6 1357.1 
ImImPyPy-(R)α-NH2γ-ImPyPyPy-(+)-
IPA (3) C64H76N23O12
+ 1358.6 1358.0 
CtPyPyIm-(R)α-NH2γ-PyImPyPy-(+)-
IPA (4) C64H73ClN21O12S
+ 1394.5 1394.1 
PyImPyIm-(R)α-NH2γ-PyImβIm-(+)-
IPA (5) C60H74N23O12
+ 1308.6 1309.0 
ImImIm-(+)-IPA (6) C30H38N11O6+ 648.3 648.8 
ImImImPy-(R)α-NH2γ-PyPyPyPy-(+)-
4PEG-Biotin (1b) C77H107N26O16S
+ 1683.8 1683.1 
 
 
described protocols. 65,66 Polyamide 5 was synthesized on hydrazine resin (855037, 
Novabiochem) in the same manner as the other polyamides and cleaved from resin in the 
same manner after 10 minute oxidation of the hydrazine by Cu(II)SO4 in pyridine and 
DMF. Polyamides were purified by reverse-phase HPLC and lyophilized. EZ-Link NHS-
PEG4-biotin (Pierce) was conjugated in 5% Hünig’s base in DMF. Purity and identity of 
compounds were verified by analytical HPLC and matrix-assisted laser 
desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry (Table 3.6).  
Brefeldin A was purchased from BD biosciences, 7-AAD from eBiosciences), and 
Z-VAD-fmk from Promega. Antibodies purchased from Abcam are: polyclonal rabbit 
anti-calreticulin (ab2907), polyclonal rabbit anti-ERp57 (ab10287), and polyclonal goat 
anti-rabbit Alexa Fluor 488 (ab150081). Antibodies from Life Technologies are: anti-
Annexin  
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Figure 3.11  Specificity control for CRT 
primary antibody.  
 
V Alexa Fluor 488 conjugate (A13201) and mouse monoclonal anti-actin (AM4302). 
Antibodies from Cell Signaling Technologies are: rabbit polyclonal anti-PARP (9542) 
and rabbit monoclonal anti-phospho-H2AX (ser139, 9718).  
Cell culture. Raji cells (ATCC) were maintained in RPMI media (Life 
Technologies) with 10% fetal bovine serum (Omega Scientific) and 5mM glutamine 
(Life Technologies). K562 cells (ATCC) were cultured in IMDM (ATCC) media and 
10% FBS. A549 and PC3 cells (ATCC) were maintained in Kaign’s modified F-12K 
media (Gibco) supplemented with 10% FBS and 5 mM glutamine. Peripheral blood 
macrophages (Stemcell Technologies) were thawed and plated in DMEM (ATCC) and 
supplemented with 5 mM glutamine and 10% FBS for at least two days and no longer 
than six days before use. 
Flow cytometry. Raji and K562 cells were plated at 1×105 cells/ml in 96-well 
plates at 100 µl and treated immediately after plating. A549 and PC3 cells were plated in  
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1 secondary control
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Table 3.7. Cell death flow cytometry after different treatments for 24 hours. 
 
 Live Necrotic Apoptotic 2º Necrotic 
NT 86.9 (±1.6) 2.0 (±0.4) 5.8 (±1.3) 5.3 (±0.3) 
1 57.0 (±2.2) 11.9 (±1.1) 12.8 (±1.2) 18.4 (±1.2) 
2 88.1 (±1.0) 2.3 (±0.3) 5.2 (±0.9) 4.5 (±0.2) 
Eto 26.7 (±0.7) 5.3 (±0.2) 32.7 (±1.1) 35.3 (±1.0) 
 
 
Table 3.8. Timecourse of cell death flow cytometry after treatment with 1. 
 
 Live Necrotic Apoptotic 2º Necrotic 
NT 95.7 (±0.5) 1.7 (±0.4) 1.1 (±0.1) 1.5 (±0.1) 
12 h 47.5 (±1.1) 19.6 (±2.0) 14.4 (±1.1) 18.5 (±0.5) 
24 h 59.7 (±4.8) 15.6 (±1.0) 11.8 (±1.0) 12.9 (±3.0) 
48 h 79.4 (±1.5) 7.7 (±1.1) 6.7 (±0.3) 6.2 (±0.4) 
 
 
24-well plates at 6×104 cells/ml at 400 µl and were allowed to adhere overnight prior to 
treatment. Adherent cells were harvested with Accutase (Life Technologies).  
For the CRT and ERp57 detection experiments, harvested cells were washed with 
cold staining buffer: HBSS (Life Technologies) with 2.5mg/ml BSA (Amresco), 10mM 
HEPES (Life Technologies), 0.1 mM MgCl2 (Life Technologies), and DNAse (Roche). 
Cells were incubated with human FcR block (eBiosciences) and primary antibody in cold 
staining buffer. This was followed by washing and incubation with dye-conjugated anti-
rabbit secondary antibody. 7-AAD, forward- and side- scatter were used to gate for live 
cells. Secondary antibody alone was used as a control (Figure 3.11). The median  
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Table 3.9  Table of top motifs and associated e-values for three Bind-n-Seq analyses of biotin-
conjugate polyamide 1b. 
 
 
 
fluorescence intensity of live cells is normalized to non-treatment. Data was acquired on 
the FACS Calibur and analyzed with Flowjo software. Measurements and standard 
deviations are in triplicate and representative of at least two independent experiments; 
asterisk indicates p<0.05 by two-tailed Student’s t-test compared to non-treatment. 
For cell death analysis flow cytometry experiments, Raji cells were harvested 
after treatment and washed with cold staining buffer and incubated with FcR block and 
dye-conjugated anti-Annexin V.  Cells were washed with staining buffer and taken for 
immediate analysis. 7-AAD was added to samples maintained at 4 ºC and data was 
acquired soon thereafter on the MACS VYB. Data was acquired in triplicate from two 
independent experiments and analyzed with Flowjo (Table 3.7 and 3.8). 
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Bind-n-Seq of polyamide 1b. Highest affinity DNA binding sites of polyamide-
biotin conjugate 1b were determined according to previously reported methods. 43 In 
brief, polyamide 1b was equilibrated at 25 or 250 nM overnight in a DNA library of all 
possible 21mers. DNA bound to 1b was affinity purified with streptavidin magnetic 
beads (M-280 Dynabeads, Life Technologies) and eluted. Isolated DNA was amplified 
by touchdown PCR and submitted for sequencing on an Illumina HiSeq 2000 Genome 
Analyzer. The MERMADE script was used to distribute data by barcode and a fasta file 
of a random 25% of sequences was generated for DREME motif analysis. Data is 
representative of three independent experiments (Table 3.9). 
DNA thermal denaturation assay. DNA of the sequence 5’-
CTTAGGGTTAGC-3’ and its complement were purchased from Integrated DNA 
Technologies and annealed. The oligonucleotides were mixed with hairpin polyamide 1 
to a final concentration of 2 and 3 µM, respectively, in 1 mL total volume. An aqueous 
solution of 10 mM sodium cacodylate, 10 mM KCl, 10 mM MgCl2, and 5 mM CaCl2 at 
pH 7.0 was used as analysis buffer. The assay utilized a Varian Cary 100 
spectrophotometer to heat samples to 90 °C, cool to a starting temperature of 25 °C, and 
then heat at a rate of 0.5 °C/min to 90 °C. Denaturation profiles were recorded at λ = 260 
nm and melting temperatures were detected by the maximum of the first derivative. Data 
shows the combined mean and standard deviation of triplicate measurements from two 
independent experiments. 
Immunoblot assays. Raji cells were plated at 105 cells/ml in 10 cm diameter 
dishes and dosed with the indicated treatment. Cells were washed with cold PBS and 
lysed for ten minutes in lysis buffer (50 mM Tris-HCl pH 7.4, 1 mM EDTA, 150 mM 
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NaCl, 1% Triton X-100) containing protease inhibitors (Complete, Roche), 1 mM PMSF, 
and phosphatase inhibitors. Samples were clarified by centrifugation at 14,000 × g for ten 
minutes, quantified with the Bradford reagent (Bio-rad), denatured by boiling in Laemmli 
buffer (LI-COR) for 5 min, and separated by sodium dodecyl sulphate-polyacrylamide 
gel electrophoresis using AnyKD gradient gels (Biorad). Protein was transferred to a 
PVDF membrane (Millipore) and blocked with Odyssey blocking buffer (LI-COR). Both 
primary antibodies and appropriate IR-dye conjugated secondary antibodies (LI-COR) 
were incubated in blocking buffer with 0.2% Tween. Anti-actin was used to control for 
equal loading and experiments were done in at least two independent biological 
replicates. Bands were visualized on a LI-COR Odyssey infrared imager.  
ATP bioluminescence assay. Raji cells were plated into 96-well cell culture 
plates at 200 µl per well and 105 cells/ml, in quadruplicate per condition. After the 
indicated treatment, media and cells were transferred to a 96-well PCR plate and 
centrifuged at 130 × g for 5 minutes. The supernatant was collected for analysis of ATP 
content using an ATP bioluminescence kit (FLAA, Sigma). The assay was performed 
according to the manufacturer’s protocol and luminescence was measured using a 
Flexstation 3. Measurements and standard deviation are technical quadruplicate and 
biological triplicate. Asterisk indicates p<0.05 by two-tailed Student’s t-test compared to 
non-treatment. 
HMGB1 ELISA. Raji cells were plated into 96-well cell culture plates at 100 µl 
per well, 105 cells/ml, in duplicate. Cells were treated with polyamide 1 and 2 as 
indicated and the supernatant collected. HMGB1 was measured using the Shino-Test 
ELISA kit (IBL international) according to the manufacturer’s instructions on the 
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Flexstation 3. Measurement and standard deviations were determined from technical 
duplicate from two independent replicates.  
Caspase luciferase assay. Raji cells were plated into 96-well cell culture plates at 
100 µl per well and 105 cells/ml, in triplicate per condition. Media was included as a 
blank control. After the indicated treatment, media and cells were transferred to an 
opaque white 96-well plate containing 100 µl in each well of the caspase-dependent 
luciferase reagent, prepared per the manufacturer’s instructions (Caspase-Glo 3/7, 
Promega).  The mixture was left at room temperature for 1 hour prior to measurement on 
the Flexstation 3 (Molecular Devices). Measurements and standard deviations were 
determined in triplicate and done in biological duplicate. 
Metabolic activity assay. Raji cells were plated into 96-well clear bottom cell 
culture plates at 100 µl per well and 105 cells/ml, in triplicate per indicated condition. 
Media was used as a background control. Metabolic activity was assessed using the 
WST-1 reagent (Roche) per the manufacturer’s instructions. Measurements and standard 
deviations were determined in triplicate and done in biological duplicate. 
Phagocytosis assay. Peripheral blood macrophages were plated at 2 × 104 cells 
per well in 24 or 48-well plates in DMEM. Immediately prior to use, macrophages were 
washed with HBSS and stained with carboxyfluorescein diacetate succinimidyl ester 
(CFSE, eBioscience) in HBSS for 5 min. Macrophages were washed of excess dye and 
returned to DMEM for incubation. Target Raji cells were plated in 96-well plates at 1 × 
105 cells/ml in 200 µl of RPMI and treated as described. Target A549 cells were plated in 
24-well plates at 2 × 104 cells per well 15 hours before beginning treatment. After 
treatment, cells were harvested with Accutase if necessary and washed with HBSS and 
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incubated with pHrodo succinimidyl ester (Life Technologies) diluted to 2 µM in HBSS 
for 5 min. Cells were then washed by centrifugation at 150 × g, re-suspended in DMEM, 
counted on a Biorad TC10 cell counter, and 5 × 104 cells per well were added to 
macrophages. After incubation for 2.5 hours at 37 ºC, media and non-adherent cells in 
each sample were aspirated and saved. Adherent cells were trypsinized, aspirated, and 
combined with saved media mixture.  Cells were washed once with PBS and fixed in 1% 
formaldehyde and kept at 4 ºC until assessment on the MACS VYB flow cytometer. The 
percentage of phagocytosis was calculated as the percentage of double positive cells 
among fluorescein+ macrophages. Measurements and standard deviations are taken from 
three independent experiments, and asterisks indicate p<0.05 by two-tailed Student’s t-
test compared to non-treatment. 
Confocal microscopy. For images of phagocytosis, cells treated in the manner 
described above were put on 35 mm glass-bottom dishes (MatTek). Confocal images 
were acquired using a 40× oil immersion objective on a Zeiss LSM 5 Exciter microscope. 
RNA-Seq. Raji cells were plated in two 175 cm2 flasks per condition at 4×105 
cells per ml with 20 ml of RPMI in each flask. Non-treatment, 25 µM polyamide 1-, and 
25 µM polyamide 2- treatment was prepared at the same time. After 24 hours incubation, 
cells were washed with PBS twice by centrifugation and pelleted in a 15 ml falcon tube. 
The cells were suspended in Trizol and lysed by repeated extrusion from a syringe needle 
and vortexing. The samples were frozen and stored in a -80 ºC freezer, until three 
biological replicates were collected. The Trizol solution was thawed and RNA was 
isolated from Trizol (Life Technologies), and precipitated with linear acrylamide (Life 
Technologies). The RNA was washed and subjected to DNase treatment (Roche) prior to 
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quantitation. Samples each containing 10 µg of RNA in 100 µl of TE buffer was 
submitted for sequencing to the Millard and Muriel Jacobs Genetics and Genomics 
Laboratory on the Illumina Genome Analyzer.  
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Table 3.2  Genes upregulated greater than 25% after treatment with polyamide 1 for 24 hours 
compared to non-treatment. 
 
Ensembl Gene  Gene Locus Ratio NT 
fpkm 
GGGW 
fpkm 
p_val q_val 
ENSG00000122877 EGR2 chr10:64571755-
64679660 
20.33 0.10 2.09 0.0002 0.0109 
ENSG00000120738 EGR1 chr5:137801178-
137805004 
9.85 3.01 29.67 0.0000 0.0000 
ENSG00000170345 FOS chr14:75745476-
75748933 
6.90 1.96 13.54 0.0000 0.0006 
ENSG00000027869 SH2D2A chr1:156776034-
156851642 
5.08 0.40 2.03 0.0001 0.0088 
ENSG00000135625 EGR4 chr2:73518057-
73520833 
4.80 0.18 0.87 0.0000 0.0010 
ENSG00000135363 LMO2 chr11:33880121-
33913836 
4.25 8.12 34.53 0.0000 0.0000 
ENSG00000110848 CD69 chr12:9905081-
9913497 
3.04 2.71 8.24 0.0000 0.0000 
ENSG00000185022 MAFF chr22:38597888-
38612518 
3.01 1.95 5.89 0.0000 0.0012 
ENSG00000111679 PTPN6 chr12:7055630-
7070479 
3.00 82.60 247.93 0.0000 0.0000 
ENSG00000059804 SLC2A3 chr12:7917811-
8250367 
2.95 4.66 13.74 0.0000 0.0000 
ENSG00000127124 HIVEP3 chr1:41972035-
42501596 
2.70 2.37 6.40 0.0000 0.0000 
ENSG00000100985 MMP9 chr20:44637546-
44688789 
2.55 0.51 1.31 0.0000 0.0032 
ENSG00000227039 ITGB2-AS1 chr21:46305867-
46351904 
2.54 3.55 9.02 0.0008 0.0362 
ENSG00000166886 NAB2 chr12:57482676-
57607134 
2.51 22.08 55.39 0.0000 0.0000 
ENSG00000197629 MPEG1 chr11:58938902-
58980424 
2.47 0.50 1.24 0.0000 0.0000 
ENSG00000168209 DDIT4 chr10:74033677-
74035794 
2.43 72.45 176.07 0.0000 0.0000 
ENSG00000228978 TNF chr6_apd_hap1:28
59028-2860831 
2.31 1.07 2.46 0.0001 0.0053 
ENSG00000204490 TNF chr6_cox_hap2:30
52959-3055729 
2.26 1.06 2.39 0.0000 0.0010 
ENSG00000206439 TNF chr6_qbl_hap6:283
6981-2839753 
2.26 1.06 2.39 0.0000 0.0010 
ENSG00000223952 TNF chr6_mcf_hap5:29
23049-2925819 
2.26 1.06 2.39 0.0000 0.0010 
ENSG00000228321 TNF chr6_mann_hap4:2
886227-2888997 
2.26 1.06 2.39 0.0000 0.0010 
ENSG00000228849 TNF chr6_dbb_hap3:28
28884-2831654 
2.26 1.06 2.39 0.0000 0.0010 
ENSG00000230108 TNF chr6_ssto_hap7:28
74144-2876914 
2.26 1.06 2.39 0.0000 0.0010 
ENSG00000232810 TNF chr6:31543343-
31546113 
2.26 1.06 2.39 0.0000 0.0010 
ENSG00000118515 SGK1 chr6:134490383-
134639250 
2.23 23.02 51.38 0.0000 0.0000 
ENSG00000138166 DUSP5 chr10:112257595-
112271302 
2.21 18.34 40.60 0.0000 0.0000 
ENSG00000108984 MAP2K6 chr17:67410837-
67538451 
2.21 2.04 4.50 0.0000 0.0000 
ENSG00000247095 MIR210HG chr11:565659-
568457 
2.10 12.69 26.61 0.0000 0.0003 
ENSG00000161929 SCIMP chr17:5095378-
5151364 
2.09 3.69 7.71 0.0000 0.0000 
ENSG00000114268 PFKFB4 chr3:48555116-
48601206 
2.03 11.94 24.26 0.0000 0.0000 
ENSG00000158050 DUSP2 chr2:96808904-
96811179 
1.97 69.35 136.93 0.0000 0.0000 
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ENSG00000090104 RGS1 chr1:192544856-
192549161 
1.90 3.88 7.39 0.0000 0.0002 
ENSG00000160888 IER2 chr19:13261281-
13265716 
1.86 51.33 95.61 0.0000 0.0000 
ENSG00000226979 LTA chr6:31539830-
31542101 
1.82 1.98 3.60 0.0001 0.0070 
ENSG00000126860 EVI2A chr17:29335514-
29709134 
1.78 6.55 11.66 0.0000 0.0000 
ENSG00000128016 ZFP36 chr19:39897486-
39900045 
1.71 13.43 23.01 0.0000 0.0000 
ENSG00000160255 ITGB2 chr21:46305867-
46351904 
1.70 57.51 97.85 0.0000 0.0000 
ENSG00000137101 CD72 chr9:35605366-
35647096 
1.68 37.22 62.43 0.0000 0.0000 
ENSG00000185650 ZFP36L1 chr14:69254376-
69263190 
1.67 182.58 305.21 0.0000 0.0000 
ENSG00000125245 GPR18 chr13:99853027-
100038688 
1.65 3.75 6.20 0.0002 0.0136 
ENSG00000179344 HLA-DQB1 chr6:32627243-
32636160 
1.65 89.37 147.42 0.0000 0.0000 
ENSG00000112137 PHACTR1 chr6:12717892-
13328776 
1.65 10.17 16.76 0.0002 0.0112 
ENSG00000166068 SPRED1 chr15:38544526-
38649450 
1.64 7.65 12.55 0.0006 0.0270 
ENSG00000226397 C12orf77 chr12:25146357-
25150453 
1.63 8.47 13.81 0.0000 0.0006 
ENSG00000111678 C12orf57 chr12:7052140-
7055166 
1.62 36.86 59.71 0.0000 0.0000 
ENSG00000156738 MS4A1 chr11:60223224-
60238233 
1.61 436.07 701.54 0.0000 0.0000 
ENSG00000143851 PTPN7 chr1:202116140-
202130716 
1.61 44.45 71.43 0.0000 0.0000 
ENSG00000154127 UBASH3B chr11:122526382-
122685181 
1.60 23.67 37.92 0.0000 0.0004 
ENSG00000087074 PPP1R15A chr19:49375648-
49379318 
1.60 6.58 10.51 0.0000 0.0000 
ENSG00000100290 BIK chr22:43506753-
43525718 
1.59 50.13 79.62 0.0000 0.0000 
ENSG00000204852 TCTN1 chr12:111051831-
111142755 
1.56 47.20 73.58 0.0000 0.0001 
ENSG00000234883 MIR155HG chr21:26934220-
26947480 
1.55 12.54 19.48 0.0000 0.0000 
ENSG00000138821 SLC39A8 chr4:103172197-
103371167 
1.54 70.90 109.02 0.0000 0.0034 
ENSG00000198873 GRK5 chr10:120967100-
121215131 
1.54 8.25 12.69 0.0004 0.0210 
ENSG00000122884 P4HA1 chr10:74766974-
74856732 
1.53 30.26 46.31 0.0000 0.0000 
ENSG00000142227 EMP3 chr19:48828628-
48833810 
1.52 19.49 29.70 0.0000 0.0000 
ENSG00000184574 LPAR5 chr12:6728000-
6745613 
1.51 10.56 15.99 0.0000 0.0000 
ENSG00000241674 HLA-DMB chr6_qbl_hap6:413
4532-4181419 
1.50 12.75 19.15 0.0004 0.0194 
ENSG00000242386 HLA-DMB chr6_mcf_hap5:42
39256-4283840 
1.50 11.71 17.57 0.0008 0.0361 
ENSG00000239329 HLA-DMB chr6_mann_hap4:4
359616-4406503 
1.50 12.85 19.25 0.0004 0.0200 
ENSG00000241296 HLA-DMB chr6_ssto_hap7:43
33159-4430060 
1.50 11.81 17.66 0.0008 0.0361 
ENSG00000196968 FUT11 chr10:75532048-
75538821 
1.49 23.20 34.68 0.0000 0.0022 
ENSG00000109929 SC5D chr11:121163161-
121179403 
1.49 52.42 78.34 0.0000 0.0002 
ENSG00000086619 ERO1LB chr1:236305831-
236445319 
1.49 10.14 15.14 0.0004 0.0202 
ENSG00000134061 CD180 chr5:66478102-
66492627 
1.49 30.00 44.67 0.0000 0.0000 
ENSG00000242574 HLA-DMB chr6:32902405-
32949282 
1.49 6.62 9.86 0.0008 0.0364 
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ENSG00000226264 HLA-DMB chr6_dbb_hap3:41
83742-4202240 
1.49 13.07 19.42 0.0005 0.0254 
ENSG00000206493 HLA-E chr6_qbl_hap6:175
0158-1754897 
1.48 15.79 23.41 0.0000 0.0001 
ENSG00000229252 HLA-E chr6_dbb_hap3:17
50883-1755622 
1.48 15.79 23.41 0.0000 0.0001 
ENSG00000233904 HLA-E chr6_cox_hap2:19
69307-1974046 
1.48 15.79 23.41 0.0000 0.0001 
ENSG00000171223 JUNB chr19:12902309-
12904124 
1.48 62.40 92.44 0.0000 0.0000 
ENSG00000230254 HLA-E chr6_ssto_hap7:17
89533-1794272 
1.48 16.26 24.09 0.0000 0.0000 
ENSG00000242092 HLA-DMB chr6_apd_hap1:41
89389-4207888 
1.48 13.01 19.22 0.0006 0.0285 
ENSG00000122986 HVCN1 chr12:111051831-
111142755 
1.48 15.71 23.21 0.0002 0.0124 
ENSG00000140563 MCTP2 chr15:94774766-
95023632 
1.47 8.01 11.80 0.0007 0.0334 
ENSG00000236632 HLA-E chr6_mann_hap4:1
805321-1810060 
1.46 11.29 16.53 0.0000 0.0013 
ENSG00000204592 HLA-E chr6:30457243-
30461982 
1.46 11.29 16.53 0.0000 0.0013 
ENSG00000225201 HLA-E chr6_mcf_hap5:18
39107-1843846 
1.46 11.29 16.53 0.0000 0.0013 
ENSG00000146386 ABRACL chr6:139349818-
139364439 
1.45 55.89 81.21 0.0000 0.0000 
ENSG00000136286 MYO1G chr7:45002260-
45018697 
1.45 16.13 23.43 0.0000 0.0000 
ENSG00000154642 C21orf91 chr21:19135631-
19639690 
1.44 25.30 36.51 0.0000 0.0000 
ENSG00000117394 SLC2A1 chr1:43391518-
43424530 
1.44 112.09 161.77 0.0000 0.0000 
ENSG00000140398 NEIL1 chr15:75639295-
75648087 
1.44 31.03 44.64 0.0000 0.0019 
ENSG00000240409 MTATP8P1 chr1:536815-
660287 
1.43 526.42 753.97 0.0000 0.0001 
ENSG00000198355 PIM3 chr22:50354160-
50357728 
1.42 93.39 132.75 0.0000 0.0000 
ENSG00000196405 EVL chr14:100437785-
100610573 
1.42 71.85 101.83 0.0001 0.0064 
ENSG00000198502 HLA-DRB5 chr6:32485119-
32498064 
1.40 21.77 30.50 0.0000 0.0001 
ENSG00000239463 HLA-DMA chr6_mcf_hap5:42
39256-4283840 
1.40 18.89 26.41 0.0002 0.0092 
ENSG00000243215 HLA-DMA chr6_ssto_hap7:43
33159-4430060 
1.40 18.93 26.43 0.0002 0.0094 
ENSG00000243719 HLA-DMA chr6_cox_hap2:43
46929-4393826 
1.40 18.95 26.46 0.0002 0.0096 
ENSG00000243189 HLA-DMA chr6_mann_hap4:4
359616-4406503 
1.40 18.86 26.33 0.0002 0.0091 
ENSG00000242685 HLA-DMA chr6_qbl_hap6:413
4532-4181419 
1.40 18.87 26.33 0.0002 0.0091 
ENSG00000202198 RN7SK chr6:52860417-
52860748 
1.40 83.52 116.54 0.0001 0.0067 
ENSG00000168389 MFSD2A chr1:40420801-
40435638 
1.40 21.97 30.64 0.0000 0.0001 
ENSG00000204257 HLA-DMA chr6:32902405-
32949282 
1.39 18.51 25.80 0.0002 0.0116 
ENSG00000242361 HLA-DMA chr6_apd_hap1:41
89389-4207888 
1.39 26.12 36.34 0.0004 0.0199 
ENSG00000196126 HLA-DRB1 chr6:32546545-
32557625 
1.39 28.09 39.07 0.0000 0.0000 
ENSG00000227357 HLA-DRB4 chr6_ssto_hap7:38
50430-4111880 
1.39 23.95 33.30 0.0000 0.0001 
ENSG00000231021 HLA-DRB4 chr6_mcf_hap5:38
82320-3897284 
1.39 23.94 33.28 0.0000 0.0001 
ENSG00000023330 ALAS1 chr3:52232101-
52248343 
1.39 36.53 50.77 0.0012 0.0495 
ENSG00000196101 HLA-DRB3 chr6_qbl_hap6:372
0953-3734041 
1.39 65.61 91.18 0.0000 0.0000 
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ENSG00000241394 HLA-DMA chr6_dbb_hap3:41
83742-4202240 
1.39 23.65 32.86 0.0007 0.0326 
ENSG00000114480 GBE1 chr3:81538849-
81811312 
1.39 12.41 17.23 0.0000 0.0001 
ENSG00000166128 RAB8B chr15:63481667-
63559981 
1.39 20.63 28.62 0.0002 0.0117 
ENSG00000229074 HLA-DRB1 chr6_mann_hap4:3
951045-4028663 
1.39 19.23 26.68 0.0000 0.0004 
ENSG00000236884 HLA-DRB1 chr6_dbb_hap3:38
20127-3854230 
1.39 19.88 27.56 0.0000 0.0003 
ENSG00000166848 TERF2IP chr16:75661621-
75795051 
1.38 77.41 107.14 0.0000 0.0000 
ENSG00000196735 HLA-DQA1 chr6:32595955-
32614839 
1.38 93.11 128.62 0.0000 0.0000 
ENSG00000125753 VASP chr19:46010687-
46030236 
1.38 52.54 72.51 0.0000 0.0000 
ENSG00000206237 HLA-DQB1 chr6_cox_hap2:40
64608-4080088 
1.38 9.54 13.15 0.0000 0.0027 
ENSG00000206302 HLA-DQB1 chr6_qbl_hap6:385
1061-3866542 
1.38 9.54 13.15 0.0000 0.0027 
ENSG00000150347 ARID5B chr10:63661058-
63856703 
1.38 4.51 6.21 0.0000 0.0001 
ENSG00000132963 POMP chr13:29233240-
29253062 
1.38 55.20 75.95 0.0000 0.0000 
ENSG00000231679 HLA-DRB3 chr6_cox_hap2:39
34114-3947232 
1.38 50.41 69.35 0.0000 0.0000 
ENSG00000124762 CDKN1A chr6:36555310-
36932613 
1.37 50.55 69.47 0.0000 0.0000 
ENSG00000251587 LDHAP1 chr4:4895908-
4896900 
1.37 25.34 34.76 0.0000 0.0006 
ENSG00000145088 EAF2 chr3:121554029-
121605373 
1.37 34.00 46.63 0.0000 0.0000 
ENSG00000172081 MOB3A chr19:2071036-
2096269 
1.37 52.90 72.55 0.0000 0.0000 
ENSG00000197324 LRP10 chr14:23340821-
23350789 
1.37 34.45 47.24 0.0001 0.0048 
ENSG00000228080 HLA-DRB1 chr6_ssto_hap7:38
50430-4111880 
1.37 103.26 141.28 0.0000 0.0000 
ENSG00000128040 SPINK2 chr4:57676025-
57687908 
1.36 19.08 25.94 0.0004 0.0209 
ENSG00000125772 GPCPD1 chr20:5525084-
5591672 
1.35 39.26 53.18 0.0001 0.0056 
ENSG00000081189 MEF2C chr5:87803362-
88762215 
1.35 52.98 71.43 0.0000 0.0000 
ENSG00000112972 HMGCS1 chr5:43287702-
43313614 
1.35 167.15 225.30 0.0000 0.0000 
ENSG00000196923 PDLIM7 chr5:176910394-
176938275 
1.35 35.66 48.06 0.0000 0.0013 
ENSG00000001630 CYP51A1 chr7:91741464-
91810039 
1.35 32.91 44.29 0.0000 0.0020 
ENSG00000159840 ZYX chr7:143078172-
143220542 
1.34 37.08 49.76 0.0001 0.0048 
ENSG00000188765 TMSB4XP2 chr2:3642425-
3692048 
1.34 1022.50 1369.26 0.0009 0.0388 
ENSG00000226417 CLIC1 chr6_mcf_hap5:30
08685-3199991 
1.34 27.76 37.16 0.0000 0.0000 
ENSG00000226248 CLIC1 chr6_dbb_hap3:29
80383-2993114 
1.34 27.67 36.99 0.0000 0.0000 
ENSG00000230685 CLIC1 chr6_cox_hap2:32
04431-3217149 
1.34 27.69 36.99 0.0000 0.0000 
ENSG00000223639 CLIC1 chr6_ssto_hap7:30
25631-3038358 
1.34 27.69 36.99 0.0000 0.0000 
ENSG00000206394 CLIC1 chr6_qbl_hap6:298
8444-3001178 
1.34 27.68 36.98 0.0000 0.0000 
ENSG00000027697 IFNGR1 chr6:137518620-
137540586 
1.34 27.61 36.88 0.0000 0.0004 
ENSG00000226651 CLIC1 chr6_mann_hap4:2
971895-3163173 
1.34 27.81 37.13 0.0000 0.0000 
ENSG00000213719 CLIC1 chr6:31694814-
31707540 
1.33 27.72 36.98 0.0000 0.0000 
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ENSG00000236090 LDHAP3 chr2:42046886-
42047894 
1.33 25.97 34.64 0.0000 0.0027 
ENSG00000131196 NFATC1 chr18:77155771-
77289325 
1.33 31.76 42.30 0.0000 0.0000 
ENSG00000225855 RUSC1-
AS1 
chr1:155278538-
155300905 
1.33 12.88 17.15 0.0009 0.0377 
ENSG00000185607 ACTBP7 chr15:44162961-
44487450 
1.33 11.08 14.72 0.0011 0.0459 
ENSG00000172175 MALT1 chr18:56338617-
56421130 
1.32 17.57 23.28 0.0000 0.0000 
ENSG00000206240 HLA-DRB1 chr6_cox_hap2:39
98150-4028758 
1.32 214.60 284.18 0.0000 0.0000 
ENSG00000206306 HLA-DRB1 chr6_qbl_hap6:378
4599-3815217 
1.32 214.60 284.18 0.0000 0.0000 
ENSG00000163219 ARHGAP25 chr2:68906732-
69053965 
1.32 33.68 44.49 0.0000 0.0012 
ENSG00000107140 TESK1 chr9:35605366-
35647096 
1.32 50.48 66.47 0.0000 0.0000 
ENSG00000235674 LDHAP2 chr1:235824340-
236046940 
1.32 50.00 65.75 0.0000 0.0005 
ENSG00000214110 LDHAP4 chr9:14921334-
14922332 
1.31 210.58 276.09 0.0000 0.0000 
ENSG00000067064 IDI1 chr10:1034337-
1095110 
1.31 100.10 130.86 0.0000 0.0000 
ENSG00000138756 BMP2K chr4:79697495-
79860592 
1.31 40.34 52.71 0.0000 0.0001 
ENSG00000227671 MIR3916 chr1:247353152-
247372795 
1.31 25.01 32.66 0.0000 0.0000 
ENSG00000152256 PDK1 chr2:173292081-
173489823 
1.30 36.41 47.51 0.0004 0.0221 
ENSG00000235847 LDHAP7 chr2:84743578-
85046713 
1.30 48.15 62.76 0.0000 0.0012 
ENSG00000007944 MYLIP chr6:16129355-
16148479 
1.30 12.88 16.72 0.0000 0.0005 
ENSG00000112343 TRIM38 chr6:25963029-
25985348 
1.30 8.83 11.45 0.0000 0.0029 
ENSG00000175105 ZNF654 chr3:88101093-
88217879 
1.30 3.00 3.90 0.0008 0.0373 
ENSG00000102144 PGK1 chrX:77320684-
77384793 
1.30 659.51 854.94 0.0000 0.0000 
ENSG00000186480 INSIG1 chr7:155089485-
155101945 
1.30 278.05 360.10 0.0000 0.0000 
ENSG00000213574 LDHAP5 chr10:120692185-
120692807 
1.29 100.13 129.62 0.0000 0.0012 
ENSG00000105287 PRKD2 chr19:47150868-
47220384 
1.29 19.29 24.96 0.0000 0.0000 
ENSG00000162927 PUS10 chr2:61169103-
61276394 
1.29 9.97 12.88 0.0000 0.0026 
ENSG00000257473 HLA-DQA2 chr6_cox_hap2:40
55570-4061793 
1.29 94.49 121.63 0.0000 0.0000 
ENSG00000206305 HLA-DQA1 chr6_qbl_hap6:384
1980-3848260 
1.29 98.01 126.08 0.0000 0.0000 
ENSG00000104765 BNIP3L chr8:26236774-
26371608 
1.28 33.08 42.33 0.0007 0.0321 
ENSG00000101608 MYL12A chr18:3247478-
3261848 
1.28 149.26 190.74 0.0000 0.0000 
ENSG00000223551 TMSB4XP4 chr9:131102924-
131123502 
1.28 58.80 75.11 0.0003 0.0152 
ENSG00000187653 TMSB4XP8 chr4:91048685-
92523064 
1.28 4409.61 5630.75 0.0002 0.0110 
ENSG00000213290 PGK1P2 chr19:12670384-
12671919 
1.28 46.19 58.97 0.0000 0.0021 
ENSG00000099840 IZUMO4 chr19:2096379-
2099592 
1.28 29.86 38.08 0.0007 0.0302 
ENSG00000179335 CLK3 chr15:74890840-
74988633 
1.28 110.22 140.54 0.0000 0.0004 
ENSG00000162511 LAPTM5 chr1:31205315-
31230667 
1.27 172.57 219.90 0.0000 0.0000 
ENSG00000109046 WSB1 chr17:25621101-
25640657 
1.27 64.39 81.97 0.0000 0.0023 
  88 
ENSG00000170949 ZNF160 chr19:53569866-
53606687 
1.27 5.83 7.42 0.0001 0.0081 
ENSG00000008282 SYPL1 chr7:105730948-
105753022 
1.27 87.36 111.13 0.0000 0.0000 
ENSG00000137642 SORL1 chr11:121318039-
121504387 
1.27 30.67 38.99 0.0001 0.0087 
ENSG00000133985 TTC9 chr14:71108503-
71142077 
1.27 15.52 19.70 0.0000 0.0007 
ENSG00000147168 IL2RG chrX:70327253-
70331958 
1.27 206.38 261.83 0.0001 0.0036 
ENSG00000119403 PHF19 chr9:123617976-
123639606 
1.27 103.89 131.76 0.0000 0.0000 
ENSG00000228612 HK2P1 chrX:79827369-
79830106 
1.27 7.99 10.12 0.0008 0.0364 
ENSG00000205542 TMSB4X chrX:12993226-
12995346 
1.26 1091.60 1380.31 0.0000 0.0000 
ENSG00000184009 ACTG1 chr17:79476996-
79494802 
1.26 1584.63 2001.96 0.0000 0.0000 
ENSG00000149781 FERMT3 chr11:63974149-
64001824 
1.26 279.36 352.84 0.0000 0.0000 
ENSG00000156675 RAB11FIP1 chr8:37716135-
37756985 
1.26 10.06 12.69 0.0000 0.0022 
ENSG00000214297 ALDOAP2 chr10:127262939-
127371713 
1.26 127.14 160.32 0.0000 0.0005 
ENSG00000196352 CD55 chr1:207494852-
207534311 
1.26 25.22 31.79 0.0000 0.0015 
ENSG00000081320 STK17B chr2:196998289-
197041227 
1.26 67.00 84.31 0.0000 0.0016 
ENSG00000236876 TMSB4XP1 chr1:42895999-
43120335 
1.26 4349.16 5468.48 0.0001 0.0070 
ENSG00000196604 POTEF chr2:130831107-
130886795 
1.26 6.91 8.68 0.0003 0.0161 
ENSG00000167460 TPM4 chr19:16178316-
16213813 
1.25 74.12 92.96 0.0000 0.0003 
ENSG00000230043 TMSB4XP6 chr20:49411430-
49493714 
1.25 10568.2
0 
13242.6
0 
0.0000 0.0031 
ENSG00000121064 SCPEP1 chr17:55055465-
55084129 
1.25 61.98 77.66 0.0000 0.0020 
ENSG00000149925 ALDOA chr16:30064410-
30081778 
1.25 2056.86 2576.58 0.0000 0.0000 
ENSG00000114023 FAM162A chr3:122103022-
122134882 
1.25 90.07 112.70 0.0000 0.0001 
ENSG00000134046 MBD2 chr18:51679078-
51751158 
1.25 340.32 425.66 0.0006 0.0282 
ENSG00000228253 MT-ATP8 chrM:8365-9990 1.25 20644.2
0 
25740.6
0 
0.0000 0.0005 
ENSG00000102393 GLA chrX:100645811-
100669121 
1.25 33.32 41.52 0.0008 0.0373 
ENSG00000181577 C6orf223 chr6:43963459-
44045689 
1.25 26.19 32.62 0.0001 0.0040 
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Table 3.3  Genes downregulated greater than 25% after treatment with polyamide 1 for 24 hours 
compared to non-treatment. 
 
Ensembl Gene Gene Locus Ratio  NT 
fpkm 
GGGW 
fpkm 
p_val q_val 
ENSG00000258486 RN7SL1 chr14:50043389-
50081390 
0.00 19.56 0.00 0.0001 0.0070 
ENSG00000214189 ZNF788 chr19:12203077-
12225499 
0.08 0.86 0.07 0.0000 0.0020 
ENSG00000176020 AMIGO3 chr3:49711434-
49761384 
0.27 1.64 0.44 0.0004 0.0204 
ENSG00000165029 ABCA1 chr9:107543282-
107691173 
0.51 1.82 0.92 0.0000 0.0023 
ENSG00000134250 NOTCH2 chr1:120454175-
120612240 
0.58 18.54 10.84 0.0012 0.0500 
ENSG00000117016 RIMS3 chr1:41086350-
41131329 
0.60 17.81 10.61 0.0000 0.0000 
ENSG00000155792 DEPTOR chr8:120879658-
121063152 
0.60 10.15 6.08 0.0011 0.0469 
ENSG00000073282 TP63 chr3:189349204-
189615068 
0.61 18.37 11.13 0.0000 0.0000 
ENSG00000239899 RN7SL674P chr2:11674241-
11782914 
0.62 201.82 124.57 0.0000 0.0000 
ENSG00000137393 RNF144B chr6:18366966-
18469105 
0.62 84.26 52.24 0.0000 0.0000 
ENSG00000130775 THEMIS2 chr1:28199054-
28213196 
0.62 49.43 30.77 0.0000 0.0000 
ENSG00000167483 FAM129C chr19:17634109-
17664647 
0.63 3.34 2.09 0.0002 0.0094 
ENSG00000244642 RN7SL396P chr8:120874901-
120875181 
0.64 238.82 153.89 0.0000 0.0000 
ENSG00000211640 IGLV6-57 chr22:22550112-
22550686 
0.65 44.34 28.60 0.0000 0.0006 
ENSG00000230006 ANKRD36BP2 chr2:89065323-
89106126 
0.65 38.78 25.07 0.0001 0.0075 
ENSG00000239437 RN7SL752P chr3:129274017-
129325661 
0.65 135.52 87.77 0.0000 0.0002 
ENSG00000125089 SH3TC1 chr4:8183798-
8243530 
0.65 79.36 51.46 0.0000 0.0000 
ENSG00000265735 RN7SL5P chr9:8314245-
10612723 
0.65 1756.91 1144.65 0.0000 0.0000 
ENSG00000101144 BMP7 chr20:55743803-
55841685 
0.66 110.79 72.68 0.0002 0.0118 
ENSG00000240869 RN7SL128P chr6:20402397-
20493941 
0.66 260.67 172.73 0.0000 0.0000 
ENSG00000082438 COBLL1 chr2:165510133-
165705844 
0.66 30.06 19.98 0.0002 0.0111 
ENSG00000263740 RN7SL4P chr3:15708742-
15901278 
0.67 1621.44 1088.28 0.0000 0.0000 
ENSG00000211895 IGHA1 chr14:106173456-
106175002 
0.67 15.32 10.29 0.0000 0.0006 
ENSG00000101846 STS chrX:7137496-
7272851 
0.67 5.14 3.47 0.0000 0.0000 
ENSG00000163884 KLF15 chr3:126061477-
126076285 
0.68 9.27 6.26 0.0012 0.0482 
ENSG00000264462 MIR3648-1 chr21:9825831-
9826011 
0.68 1496.82 1011.79 0.0000 0.0000 
ENSG00000211897 IGHG3 chr14:106235438-
106237742 
0.68 13.25 8.98 0.0000 0.0009 
ENSG00000160856 FCRL3 chr1:157644110-
157670775 
0.68 32.28 21.96 0.0003 0.0176 
ENSG00000176533 GNG7 chr19:2511217-
2702746 
0.68 24.17 16.52 0.0000 0.0000 
ENSG00000132970 WASF3 chr13:27131839-
27263085 
0.69 6.00 4.13 0.0000 0.0000 
ENSG00000179873 NLRP11 chr19:56296769-
56393218 
0.70 4.17 2.90 0.0000 0.0002 
  90 
ENSG00000145990 GFOD1 chr6:13358061-
13487787 
0.70 11.10 7.73 0.0000 0.0000 
ENSG00000226958 RNA28S5 chrX:108297360-
108297792 
0.70 2581.19 1802.17 0.0000 0.0000 
ENSG00000112182 BACH2 chr6:90636247-
91006627 
0.70 92.93 64.95 0.0000 0.0001 
ENSG00000221963 APOL6 chr22:36044441-
36057404 
0.70 5.52 3.87 0.0000 0.0018 
ENSG00000197256 KANK2 chr19:11274943-
11308243 
0.70 28.80 20.24 0.0000 0.0000 
ENSG00000211896 IGHG1 chr14:106202679-
106209408 
0.70 120.97 85.27 0.0000 0.0000 
ENSG00000116717 GADD45A chr1:68150743-
68154021 
0.71 58.38 41.66 0.0000 0.0000 
ENSG00000166428 PLD4 chr14:105391152-
105399574 
0.72 27.51 19.76 0.0002 0.0119 
ENSG00000159842 ABR chr17:906757-
1132315 
0.72 234.84 168.72 0.0000 0.0000 
ENSG00000211893 IGHG2 chr14:106109388-
106115394 
0.72 12.84 9.25 0.0010 0.0416 
ENSG00000160505 NLRP4 chr19:56296769-
56393218 
0.72 6.00 4.33 0.0000 0.0003 
ENSG00000175040 CHST2 chr3:142838172-
142841800 
0.72 10.68 7.71 0.0000 0.0001 
ENSG00000155966 AFF2 chrX:147582138-
148082193 
0.72 9.50 6.88 0.0000 0.0005 
ENSG00000221930 FAM45B chrX:129611042-
129658231 
0.73 12.32 8.93 0.0009 0.0389 
ENSG00000054654 SYNE2 chr14:64319682-
64805317 
0.73 183.41 133.35 0.0000 0.0000 
ENSG00000168016 TRANK1 chr3:36868310-
36986548 
0.73 62.79 45.67 0.0000 0.0017 
ENSG00000169750 RAC3 chr17:79989499-
79992080 
0.73 26.90 19.64 0.0000 0.0022 
ENSG00000211892 IGHG4 chr14:106090686-
106092403 
0.73 18.42 13.53 0.0002 0.0097 
ENSG00000164691 TAGAP chr6:159455499-
159466184 
0.73 14.62 10.74 0.0000 0.0001 
ENSG00000105327 BBC3 chr19:47724078-
47736023 
0.74 9.86 7.26 0.0001 0.0084 
ENSG00000184384 MAML2 chr11:95709761-
96076382 
0.74 1.99 1.47 0.0008 0.0346 
ENSG00000149639 SOGA1 chr20:35405844-
35492089 
0.74 12.62 9.33 0.0000 0.0000 
ENSG00000149418 ST14 chr11:130029456-
130080356 
0.74 60.33 44.74 0.0000 0.0000 
ENSG00000254709 IGLL5 chr22:23229959-
23238014 
0.74 354.62 263.92 0.0000 0.0000 
ENSG00000117148 ACTL8 chr1:18081807-
18153558 
0.75 19.18 14.29 0.0000 0.0013 
ENSG00000185838 GNB1L chr22:19744225-
19842462 
0.75 24.82 18.51 0.0005 0.0237 
ENSG00000211978 IGHV5-78 chr14:107259337-
107259632 
0.75 237.09 177.14 0.0001 0.0059 
ENSG00000065057 NTHL1 chr16:2089815-
2185899 
0.75 98.92 73.91 0.0000 0.0000 
ENSG00000135144 DTX1 chr12:113494513-
113535833 
0.75 413.55 309.92 0.0000 0.0000 
ENSG00000088305 DNMT3B chr20:31350190-
31397162 
0.75 7.95 5.97 0.0001 0.0047 
ENSG00000128965 CHAC1 chr15:41245159-
41248710 
0.75 18.76 14.09 0.0005 0.0250 
ENSG00000119139 TJP2 chr9:71736208-
71870124 
0.75 25.64 19.26 0.0006 0.0266 
ENSG00000184524 CEND1 chr11:787103-
790123 
0.75 51.17 38.56 0.0004 0.0221 
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Table 3.4  Genes upregulated greater than 25% after treatment with polyamide 2 for 24 hours 
compared to non-treatment. 
 
Ensembl Gene Gene Locus Ratio NT 
fpkm 
GWWC 
fpkm 
p_val q_val 
ENSG00000125675 GRIA3 chrX:122318005-
122624766 
N/A 0.00 1.30 0.0000 0.0025 
ENSG00000164076 CAMKV chr3:49895420-
49907655 
N/A 0.00 2.94 0.0000 0.0000 
ENSG00000070808 CAMK2A chr5:149569519-
149669854 
N/A 0.00 0.61 0.0000 0.0006 
ENSG00000154188 ANGPT1 chr8:108261720-
108510283 
N/A 0.00 0.50 0.0000 0.0024 
ENSG00000127152 BCL11B chr14:99635623-
99737861 
16.50 0.07 1.14 0.0000 0.0000 
ENSG00000239527 RPS23P7 chr17:60447578-
60493837 
10.63 0.54 5.69 0.0001 0.0050 
ENSG00000253556 MTCO1P4 chr8:104101023-
104102899 
9.79 0.10 1.00 0.0003 0.0148 
ENSG00000214204 HNRNPA1P43 chr1:116399481-
116400440 
5.03 0.30 1.50 0.0006 0.0293 
ENSG00000101335 MYL9 chr20:34894257-
35274619 
3.91 0.33 1.30 0.0005 0.0260 
ENSG00000213704 EEF1A1P15 chrX:97644507-
97645918 
3.78 0.79 2.98 0.0000 0.0000 
ENSG00000188042 ARL4C chr2:235401684-
235405697 
3.32 0.15 0.48 0.0002 0.0094 
ENSG00000081059 TCF7 chr5:133450401-
133487556 
3.22 2.74 8.83 0.0000 0.0002 
ENSG00000213128 RPL32P31 chr17:78516002-
78516405 
3.19 2.12 6.76 0.0010 0.0421 
ENSG00000197956 S100A6 chr1:153506078-
153508720 
3.10 5.91 18.33 0.0000 0.0000 
ENSG00000237882 PPIAP13 chr10:76849005-
76849483 
2.83 2.56 7.24 0.0002 0.0110 
ENSG00000200312 RN7SKP255 chr14:89591214-
90421121 
2.16 18.53 40.03 0.0000 0.0005 
ENSG00000200488 RN7SKP203 chr2:76672204-
76672536 
2.07 20.64 42.74 0.0000 0.0001 
ENSG00000202198 RN7SK chr6:52860417-
52860748 
1.90 83.52 158.42 0.0000 0.0000 
ENSG00000201428 RN7SKP71 chr12:112597991-
112819896 
1.76 31.94 56.11 0.0000 0.0015 
ENSG00000186834 HEXIM1 chr17:43224683-
43236822 
1.40 5.98 8.35 0.0000 0.0000 
ENSG00000176393 RNPEP chr1:201951499-
201986316 
1.26 88.42 111.35 0.0000 0.0005 
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Table 3.5  Genes downregulated greater than 25% after treatment with polyamide 2 for 24 hours 
compared to non-treatment. 
 
Ensembl Gene ID Gene Locus Ratio NT 
fpkm 
GWWC 
fpkm 
p_val q_val 
ENSG00000260280 SLX1B-SULT1A4 chr16:29262828-
29606395 
0.00 1.58 0.00 0.0000 0.0001 
ENSG00000134532 SOX5 chr12:23682439-
24103966 
0.44 17.01 7.56 0.0000 0.0013 
ENSG00000131374 TBC1D5 chr3:17199898-
18568819 
0.45 18.98 8.54 0.0000 0.0000 
ENSG00000184903 IMMP2L chr7:110303109-
111202573 
0.49 15.84 7.81 0.0002 0.0121 
ENSG00000131558 EXOC4 chr7:132937828-
133751342 
0.51 99.41 50.51 0.0000 0.0000 
ENSG00000145996 CDKAL1 chr6:20534687-
21232635 
0.57 7.13 4.04 0.0000 0.0011 
ENSG00000139734 DIAPH3 chr13:60239716-
60738119 
0.61 7.93 4.83 0.0000 0.0000 
ENSG00000119522 DENND1A chr9:126118448-
126692431 
0.62 45.22 27.97 0.0000 0.0003 
ENSG00000073282 TP63 chr3:189349204-
189615068 
0.64 18.37 11.68 0.0000 0.0000 
ENSG00000164808 SPIDR chr8:48173166-
48648868 
0.64 128.25 82.62 0.0000 0.0000 
ENSG00000155966 AFF2 chrX:147582138-
148082193 
0.65 9.50 6.16 0.0000 0.0000 
ENSG00000112699 GMDS chr6:1624040-
2245926 
0.65 33.89 22.14 0.0001 0.0037 
ENSG00000141627 DYM chr18:46550072-
46987717 
0.66 58.64 38.58 0.0000 0.0001 
ENSG00000111880 RNGTT chr6:89319984-
89673348 
0.67 12.09 8.10 0.0000 0.0000 
ENSG00000133195 SLC39A11 chr17:70642087-
71088851 
0.67 42.03 28.21 0.0000 0.0007 
ENSG00000049323 LTBP1 chr2:33172038-
33624576 
0.67 23.00 15.48 0.0003 0.0138 
ENSG00000198846 TOX chr8:59717976-
60033905 
0.68 4.89 3.31 0.0000 0.0001 
ENSG00000170396 ZNF804A chr2:185463092-
185804219 
0.68 4.11 2.80 0.0000 0.0002 
ENSG00000144535 DIS3L2 chr2:232825954-
233209060 
0.68 21.08 14.37 0.0004 0.0190 
ENSG00000156110 ADK chr10:75910959-
76469061 
0.68 38.74 26.51 0.0000 0.0000 
ENSG00000167216 KATNAL2 chr18:44526786-
44628613 
0.69 3.13 2.16 0.0009 0.0397 
ENSG00000184384 MAML2 chr11:95709761-
96076382 
0.69 1.99 1.38 0.0001 0.0069 
ENSG00000184220 CMSS1 chr3:99536677-
99897447 
0.69 88.52 61.50 0.0000 0.0000 
ENSG00000091157 WDR7 chr18:54318615-
54698828 
0.70 3.61 2.51 0.0000 0.0000 
ENSG00000174891 RSRC1 chr3:157813742-
158288855 
0.70 23.63 16.44 0.0000 0.0017 
ENSG00000259660 DNM1P47 chr15:102291234-
102334505 
0.70 0.60 0.42 0.0009 0.0391 
ENSG00000137393 RNF144B chr6:18366966-
18469105 
0.70 84.26 58.92 0.0000 0.0000 
ENSG00000152061 RABGAP1L chr1:174084437-
174964445 
0.70 93.94 65.86 0.0000 0.0000 
ENSG00000185104 FAF1 chr1:50905149-
51425935 
0.70 65.35 45.88 0.0000 0.0000 
ENSG00000153317 ASAP1 chr8:131064352-
131455906 
0.71 29.49 20.80 0.0007 0.0306 
ENSG00000049618 ARID1B chr6:157099062-
157530401 
0.71 24.14 17.20 0.0000 0.0000 
  93 
ENSG00000182247 UBE2E2 chr3:23244510-
23633284 
0.71 29.49 21.03 0.0000 0.0004 
ENSG00000117090 SLAMF1 chr1:160577889-
160617085 
0.71 27.01 19.30 0.0000 0.0003 
ENSG00000138623 SEMA7A chr15:74701629-
74726808 
0.72 22.73 16.31 0.0010 0.0431 
ENSG00000054654 SYNE2 chr14:64319682-
64805317 
0.72 183.41 131.71 0.0000 0.0000 
ENSG00000153015 CWC27 chr5:64064756-
64314418 
0.72 24.69 17.79 0.0000 0.0027 
ENSG00000197157 SND1 chr7:127292233-
127732661 
0.73 610.24 446.33 0.0000 0.0000 
ENSG00000155849 ELMO1 chr7:36893960-
37488852 
0.73 86.24 63.11 0.0000 0.0000 
ENSG00000005810 MYCBP2 chr13:77618791-
77901185 
0.73 82.32 60.25 0.0000 0.0005 
ENSG00000176463 SLCO3A1 chr15:92396924-
92874267 
0.73 41.59 30.47 0.0010 0.0411 
ENSG00000156639 ZFAND3 chr6:37787274-
38122400 
0.73 32.89 24.13 0.0007 0.0309 
ENSG00000038382 TRIO chr5:14143810-
14532235 
0.74 103.50 76.21 0.0003 0.0138 
ENSG00000010803 SCMH1 chr1:41492871-
41707826 
0.74 57.57 42.68 0.0010 0.0416 
ENSG00000235823 LINC00263 chr10:102133371-
102143125 
0.74 5.92 4.41 0.0008 0.0338 
ENSG00000075151 EIF4G3 chr1:21132971-
21503377 
0.74 111.99 83.41 0.0000 0.0000 
ENSG00000144645 OSBPL10 chr3:31699381-
32119072 
0.75 112.81 84.50 0.0000 0.0001 
ENSG00000198648 STK39 chr2:168810529-
169104651 
0.75 21.20 15.90 0.0003 0.0170 
ENSG00000145349 CAMK2D chr4:114372187-
114683083 
0.75 39.19 29.50 0.0001 0.0079 
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Chapter 4 
 
 
 
Synthesis and toxicology studies of a Py-Im polyamide targeted 
 to the CTG•CAG-repeat sequence of Myotonic Dystrophy 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This research was conducted in collaboration with Alissa A. Hare, Alexis A. Kurmis, 
Jordan L. Meier, Fei Yang, and Peter B. Dervan (California Institute of Technology) and 
with Joel Gottesfeld and Jintang Du (Scripps Research Institute).   
  99 
Abstract 
 
Myotonic dystrophy type 1 (DM1) is a neuromuscular disease caused by an expansion of 
CTG•CAG triplet repeats which, when transcribed into mRNA, sequesters the RNA 
splicing regulator muscleblind-like protein from its normal function and causes clinical 
pathology. DNA binding Py-Im polyamides targeted to the CTG•CAG triplet repeat 
sequence may be useful towards disrupting transcription of the toxic RNA. In this study, 
we assess the toxicity of two polyamides in mice to inform tolerable dosing regimens to 
be examined in a DM1 mouse model. We found that subcutaneously injected hairpin 
polyamide 2 targeted to 5’-(A/T)GC(A/T)GC(A/T)-3’ is absorbed and circulates in a 
fashion similar to previously studied eight-ring polyamides. However, polyamide 2 dosed 
three times a week displayed toxicity at low (1 mg/kg) doses and serum chemistry 
showed liver and kidney damage at a single dose of 5 and 10 mg/kg. Polyamide 3, which 
differs only by an acetylation at the butyric acid turn unit, showed no toxicity at a single 
dose of up to 9 mg/kg but was dose limited by solubility. This study suggests polyamide 
3 is a better tolerated compound and should be assessed for circulation and multiple dose 
toxicity, but its formulation should be improved. 
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4.1  Introduction 
Myotonic dystrophy type 1 (DM1) is an inherited neuromuscular disorder with a 
wide-spectrum of clinical pathologies which include dysfunction of skeletal muscles, 
cardiac defects, and cataracts.1 The disease is caused by a pathological expansion of 
CTG•CAG triplet repeats at the 3’ untranslated region of the gene encoding serine-
threonine protein kinase DMPK1.2 The expanded triplet repeats are transcribed into 
mRNA, which sequesters the RNA splicing regulator muscleblind-like 1 protein 
(MBNL1) to form nuclear foci.3 MBNL1 governs exon splicing in a selection of genes 
and its sequestration results in splicing defects that cause clinical toxicity (Figure 4.1).4 
 
Disease models and phenotypic assays have been developed to discover means to 
disrupt this pathology. In cell culture, potential therapeutic strategies can be screened for 
reduction in the number of toxic nuclear foci. For screening in animals, Thornton and 
coworkers have developed a mouse model with muscle-specific expression of skeletal  
 
 
 
Figure 4.1  Diagram of the molecular cause of Myotonic Dystrophy type 1. 
Pathogenic RNA transcribed from expanded CTG•CAG triplet repeats binds 
MBNL1. MBNL1 is not available to perform its normal RNA splicing functions 
and results in toxicity. 
Expanded repeats 
in the 3’ UTR
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 actin containing the expanded triplet repeats.5 The model successfully recapitulated 
sequestration of MBNL1, splicing defects, and myotonia. This model has been used to 
show that RNA interference technology can prevent sequestration of MBNL1 and reverse 
pathology.6 RNA interference is a reasonable method to degrade the triplet-repeat 
expanded transcripts after their production, but its therapeutic utility is challenged by 
poor organismal distribution.7 An alternative approach to reducing toxic mRNA is to 
decrease the transcription of the expanded repeat sequence, which potentially can be 
accomplished by sequence-specific DNA-binding small molecules. 
 
Py-Im polyamides are a class of programmable, sequence-specific small 
molecules that bind in the minor groove of DNA.8-13 Sequence preference is achieved by 
side-by-side pairings of aromatic amino acids that distinguish the edges of the four 
Watson-Crick base pairs according to the pairing rules: Im/Py codes for a G•C base pair 
and Py/Py binds both T•A/A•T in preference to G•C/C•G.11-14 Eight-ring hairpin 
polyamides linked by a central aliphatic γ-aminobutyric acid unit have affinities for 
match sites with Ka’s  from 108 to 1010 M-1.9,15 Targeting longer sequences in this hairpin 
motif is challenging because the oligomers are over-curved compared to DNA.16,17  To 
relax the curvature of oligomers targeting longer sequences, β alanine (β) can be 
substituted for Py-rings in some cases such that β/β pairs replace Py/Py for T•A/A•T 
specificity.16-18  Access to chromatin without transfection agents has been demonstrated 
by fluorescent dye conjugates of cell-permeable polyamides which localize to the nucleus 
in live cells.19,20  Hairpin polyamides have been shown to downregulate transcription of  
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Figure 4.2  Structures of polyamides synthesized for this study. Polyamide 1-3 
contain the same core and target the same 5’-(A/T)GC(A/T)GC(A/T)-3’ sequence 
contained in the triplet repeat sequence but differ at the C-terminal tail and the 
hairpin turn unit. 
 
associated genes when targeted to the consensus sequences of binding sites of 
transcription factors in both cells and xenograft models in mice.21-25 A Py-Im polyamide 
targeted to the CTG•CAG repeat sequence may downregulate the transcription of the 
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Table 4.1  Thermal stabilization of DNA by 2β2 polyamides. 
 
 
 
DMPK1 gene which causes the DM1 pathology. Studies in mouse models have shown 
Py-Im polyamides circulate with good distribution and pharmacokinetic profiles,26,27 such 
that Py-Im oligomers may provide an avenue for therapeutic benefit. 
 
4.2  Results 
Py-Im polyamides 1, 2, and 3 are hairpin polyamides with 2 aromatic rings 
β−alanine and 2 aromatic rings on each strand (2β2), designed and synthesized to target 
the CTG•CAG repeat sequence (Figure 4.2). Their DNA binding to the CTG repeat 
sequence 5’-ACTGCTGCTGAT-3’ was verified by a DNA thermal denaturation 
experiment, which correlates with binding affinity. 28 The results show robust 
stabilization of the duplex DNA by all three polyamides, with ΔTm values of 16.7 ºC, 
19.1 ºC, and 14.2 ºC for 2β2 hairpins 1, 2, and 3, respectively (Table 4.1).  In on-going 
studies, these compounds are being evaluated by our collaborators in the Gottesfeld 
group in a cell culture model of DM1. Induced pluripotent stem cells (iPSC) with  
 
5’-A C T G C T G C T G A T -3’
3’-T G A C G A C G A C T A -5’
DNA only 57.0 (±0.3) - -
Tm ºC ∆Tm ºC
19.12 76.2 (±0.1)+ +IPA
16.71 73.7 (±0.2)+ +IPA
14.23 71.2 (±0.2)+IPA NHAc
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Figure 4.3  Circulation study of polyamide 2 in 
normal C57BL/6 male mice. Single subcutaneous dose 
in 20% DMSO/PBS given to four mice, two mice per 
time point. Concentrations were obtained by analytical 
HPLC against an internal standard.  
 
CTG•CAG expanded repeats were produced using transcription factor reprogramming of 
DM1 patient fibroblasts. As their preliminary results suggested a reduction in nuclear 
RNA foci, we began studies in parallel to assess the toxicity of the compounds in normal 
mice. The aim of this study is to assess toxicity to inform tolerable dosing regimens to be 
examined for efficacy in the expanded-repeat DM1 mouse model. 
 
We first chose to assess hairpin polyamide 2 in mice with the consideration that 
the C-terminal tail structure without the β−alanine has been better characterized in both 
live cell and mouse studies, and its solubility properties were better than that of 3. To 
confirm circulation of the hairpin polyamide, 4 normal C57BL/6 mice were injected 
subcutaneously with polyamide 2 at a concentration 2.5 mg/kg. We applied a single dose 
at 200 µl and were limited by the solubility of the compound in the vehicle, 20% DMSO 
in PBS. Nevertheless, we detected the compound in the blood stream within half an hour 
of injection at 2.7 µM (Figure 4.3). The dip in concentration at 1 hour is likely variability 
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between mice because time points are alternated between groups of two mice each; this 
would likely average out with more replicates. At 8 hours and 24 hours, the detected 
peaks are near the lower detection limit for the HPLC. In proportion to the amount of 
polyamide 2 injected, the concentration and time course of elimination is similar to that 
previously observed with subcutaneously injected eight-ring hairpins.26  
To achieve higher doses in a single dose experiment of toxicity, we exchanged 
PBS for saline in the vehicle, which allowed us to achieve concentrations of 5 mg/kg per  
200 µl injection. On day 0, we injected male C57BL/6 mice subcutaneously with one or 
two injections to achieve doses of 5 mg/kg (n = 3) and 10 mg/kg (n = 1), respectively, 
and observed their weight over 9 days (Figure 4.4A and 4.4B). By day 6, the mouse 
dosed at 10 mg/kg had lost over 15% of its weight and had to be euthanized. At day 9, the 
end of the study, mice dosed at 5 mg/kg were distressed and averaged 87% of their initial 
weight (n=3). Blood serum was obtained from the mice at the end of the study or upon 
sacrifice for blood chemistry analysis. We found a large elevation of aspartate 
transaminase (AST), alanine transaminase (ALT), and total bilirubin in the blood, 
indicative of liver toxicity in a dose dependent manner (Table 4.2). Blood urea nitrogen 
(BUN) and creatinine are also elevated, suggesting the mice sustained kidney damage as 
well (Table 4.2). This showed the maximum tolerated single dose is under 5 mg/kg for 
polyamide 2.  
 
We next explored lower doses in anticipation of multiple dose studies. At 1 mg/kg 
(n = 1) and 2 mg/kg (n = 1), there was no decrease in weight observed over the 9 days  
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Figure 4.4  Weight curve studies with polyamide 2. A) Schedule of dosing and observation for 
single dose study with polyamide 2. B) Weight curves for escalating single doses: 1, 2, 5, and 10 
mg/kg dosed subcutaneously in 20% DMSO/saline. C) Schedule of dosing and observation for 
multiple dose study with polyamide 2. D) Weight curves for multiple doses at 1 or 2 mg/kg 
dosed subcutaneously. Mice were euthanized prior to end of study due to weight loss greater 
than 15%. 
following injection (Figure 4.4B). We then assessed the tolerability of hairpin 2 after 
multiple dose exposure at these concentrations. The study was designed for three 
injections per week, for two weeks (Figure 4.4C). Mice were injected at 1 mg/kg (n = 2) 
and 2 mg/kg (n = 2) and their weights monitored. Mice injected at 2 mg/kg lost more than 
15% of their weight by day 9 and were euthanized. Mice injected at 1 mg/kg were 
euthanized after losing more than 15% of their body weight by day 10, such that no mice 
survived the experiment (Figure 4.4D).  
 
Given the significant toxicity observed with polyamide 2, we tested polyamide 3, as 
previous studies have indicated acetylation of the amine on the γ-butyric acid turn unit 
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Table 4.2  Serum chemistry analysis for liver and kidney toxicity. 
 
Polyamide ALT AST Bilirubin BUN Creatinine 
Normal 57 ±40 194 ±152 0.32 ±0.3 23.6 ±4.8 0.34 ±0.12 
Vehicle 17 45 0.1 30 0.2 
1     5 mg/kg 1343 798 0.3 50 0.7 
1   10 mg/kg 1944 1297 0.2 79 0.9 
 
 
can improve the toxicity profile.29 Polyamide 3 was dissolved in 20% DMSO in saline, 
but was only soluble to 2.5 mg/kg. Doses of 9 mg/kg (n = 1) and 5 mg/kg (n = 1) were 
achieved with 4 and 2 injections, respectively. Despite the large volume of vehicle 
injected into the mice, both doses showed no toxic effect on the mice, and the mice 
gained weight through the 9 days of observation (Figure 4.5A and B). These results 
suggest the 2β2 hairpins 2 and 3 follow the same pattern of reduced toxicity shown for 
eight-ring hairpins upon acetylation of the amine on the turn unit. 
 
4.3  Discussion 
 From these studies we have found that the 2β2 hairpin polyamide 2 circulates in a 
fashion similar to eight ring polyamides dosed subcutaneously. However, we found that 
polyamide 2 is toxic at a single dose of 5 mg/kg and at 1 mg/kg dosed three times a week. 
Indeed, a single injection at 5 and 10 mg/kg caused liver and kidney damage. This 
compound is likely too toxic for long term dosing in the DM1 mouse model. Due to this 
toxicity, the acetylated 2β2 hairpin 3 was examined. Polyamide 3 showed a more 
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Figure 4.5  Weight curve studies with polyamide 3.  
A) Schedule of dosing and observation for single 
dose study with polyamide 3. B) Weight curves for 
single doses delivered in 2 or 4 subcutaneous 
injections of 20% DMSO/saline. 
 
favorable tolerability profile by weight assessment after a single dose at 5 and 9 mg/kg, 
dose levels that caused toxicity in with polyamide 2. The circulation of this compound 
and its tolerability after multiple doses remains to be tested.  
 
The insolubility of the acetylated 2β2 oligomer 3 in the 20% DMSO/saline 
vehicle will limit achievable compound exposure in the mouse model and motivates 
exploration of improved formulation. While dose titration will be an iterative process 
with the efficacy model, an improved formulation will be advantageous for testing higher 
concentrations. It remains to be studied whether an alteration in formulation will 
substantively change the pharmacokinetic and toxicity profiles of the polyamide. The 
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establishment of a well-tolerated dosing window in mice will be the first step towards 
assessing the utility of 2β2 hairpin polyamides for addressing DM1 pathology. 
 
4.4  Materials and Methods 
 Synthesis of polyamides. Hairpin polyamide 1 was synthesized on β-alanine 
Pam-resin and polyamides 2 and 3 were synthesized on Kaiser oxime resin as previously 
described.30-32 Polyamides were purified by preparatory HPLC and the purity and identity 
determined by analytical HPLC and MALDI-TOF (Table 4.3). 
 Thermal denaturation studies. The DNA oligomer 5’-ACTGCTGCTGAT-3’ 
and its complement were purchased from Integrated DNA Technology and annealed to 
form duplex DNA. DNA and each hairpin polyamide was mixed to a final concentration 
of 2 and 3 µM, respectively, in 1 mL total volume. The buffer was an aqueous solution of 
10 mM sodium cacodylate, 10 mM KCl, 10 mM MgCl2, and 5 mM CaCl2 at pH 7. A 
Varian Cary 100 spectrophotometer with a thermocontroller was used for measurements 
at λ = 260 nm with a path length of 1 cm. Samples were heated to 90 °C and cooled to a 
starting temperature of 25 °C and then heated at a rate of 0.5 °C/min to 90 °C to record 
denaturation profiles. Melting temperature was defined as the maximum of the first 
derivative of the denaturation profile. Data is the mean of four measurements. 
Mouse studies. All animal experiments were conducted under an IACUC 
approved protocol at the California Institute of Technology. 6-8 week old male 
C57BL/6J mice were purchased from Jackson Laboratory and allowed to acclimate for at 
least 3 days. 
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Table 4.3  Masses of polyamides by MALDI-TOF. 
 
Polyamide Formula [Mass + H] Found Mass 
1 C72H90N27O15+ 1572.7 1572.7 
2 C69H85N26O14+ 1501.7 1501.6 
3 C71H87N26O15+ 1543.7 1543.7 
 
 
 Circulation of compound 2.  The circulation experiment was conducted as 
previously described for 8-ring hairpin polyamide analyses. 26 Four acclimatized 8-week 
old male C57BL/6J mice were separated into two cages and all dosed with polyamide 2 
in a subcutaneous single injection in the flank. Solubility limited the concentration to 2.5 
mg/kg dosed in 200 µl of 20% DMSO/PBS. Blood was obtained by retro-orbital 
collection at 0.5, 1, 2, 8, and 24 hours from alternating pairs of mice. The blood from two 
mice was combined and serum isolated by centrifugation at 6000 × g for 5 minutes. 40 µl 
of serum was combined with 80 µl of MeOH and vortexed to precipitate proteins. The 
samples were centrifuged at 16000 × g and 90 µl of the supernatant removed to a new 
tube. An equal volume of 20% acetonitrile in 0.1% TFA/water was added. 20 µl of an 
internal standard, Boc-Im-OEt, (~ 1 mg in 10 ml water) water was spiked into 180 µl of 
sample.  
The samples were analyzed on a Beckman Gold analytical HPLC with a 
Phenomenex Kinetex C18 analytical column (100 mm × 4.6 mm, 2.6 µm). Peaks for 
polyamide 2 were quantitated by integration at 304 nm relative to the internal standard 
and determined by interpolation on a standard curve. A standard curve of concentration 
versus integrated area was generated by diluting known concentrations of polyamide 2 
into C57BL/6 serum and preparing the samples with the internal standard in the same 
manner as above. 
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 Single dose or multiple dose animal weight loss. Animals were injected at the 
described doses and schedules with U-100 insulin syringes (UltiCare). Treatment was 
given subcutaneously in 20% DMSO in saline or PBS as vehicle. Animals were 
monitored daily for weight for 9 or 14 days (single dose or multiple dose, respectively) 
and sacrificed if weight loss was greater than 15%.  
 Serum chemistry analysis.  Serum analysis was conducted as previously 
described. 29 In brief, blood from treated mice was obtained by retro-orbital bleeding 
(Drummond) and serum isolated after centrifugation at 6000 × g for 5 minutes. Serum 
ALT, AST, total bilirubin, BUN, and creatinine levels was analyzed at IDEXX-RADIL. 
Normal values are reported from The Jackson Laboratory 
(http://jaxmice.jax.org/strain/000664.html). 
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Chapter 5 
 
 
 
Towards understanding genome-wide Py-Im polyamide 
perturbation of Hypoxia-Inducible Factor by ChIP-seq 
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Abstract 
The adaptive response to low oxygen is mediated by the transcription factor Hypoxia-
Inducible Factor (HIF) and can be co-opted by cancer cells to promote its survival. A 
DNA minor groove binding Py-Im polyamide targeted to the hypoxia response element 
DNA sequence has been previously reported to disrupt a portion of the HIF 
transcriptional program. In this study, we explore the genome-wide perturbation of HIF 
occupancy under hypoxia by a Py-Im polyamide employing immunoprecipitation 
coupled to next generation sequencing, ChIP-seq. The study revealed an enrichment of 
the HRE consensus motif in sequenced reads and mapped peaks of enrichment in the 
promoter regions of known hypoxia genes with good resolution. The peaks could be 
quantified and differential occupancy upon hypoxia induction and reduced occupancy 
upon polyamide treatment could be measured. This study provides an early step towards 
revealing the effects of Py-Im polyamides on transcription factor occupancy and 
understanding its relation to transcriptional modulation. 
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5.1  Introduction 
Cells and tissues have an adaptive transcriptional response to chronic and acute 
hypoxia, or low oxygen, primarily controlled by the heterodimeric transcription factor 
Hypoxia-Inducible Factor (HIF).1,2 The HIF-α and HIF-β heterodimer controls the 
expression of genes involved in erythropoiesis, angiogenesis, metabolism, and cell 
death.3-6 HIF-α functions as an oxygen sensing system through its constituitive 
translation and immediate, molecular oxygen-dependent proteasomal degradation under 
normoxic conditions (Figure 5.1).7 Prolyl hydroxylase enzymes (PHD) were identified as 
the effectors of HIF-α degradation.8,9 The PHDs use molecular oxygen, with catalytic 
iron and 2-oxoglutarate as co-factors, to hydroxylate HIF-α.10 The hydroxylated HIF-α is 
recognized by the E3 ubiquitin ligase protein Von-Hippel Lindau (VHL) and tagged with 
ubiquitin for proteasomal degradation (Figure 5.1).11 In hypoxic conditions, the lack of 
molecular oxygen prevents hydroxylation by PHDs and allows HIF-α to escape 
proteasomal degradation. HIF-α forms a heterodimer with HIF-β, translocates to the 
nucleus, and binds the hypoxia response element (HRE). The HIF heterodimer, with co-
activators p300/CBP, then activates the transcription of genes that regulate cellular and 
tissue adaptation to hypoxia.12 
 
Means to modulate HIF genes have been the subject of investigation due to its 
potential therapeutic value.13 Many cancers grow beyond their access to vasculature and 
create a microenvironment of hypoxia. The adaptive response to hypoxia can give a 
survival advantage to these cells through the expression of genes that promote  
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Figure 5.1  Molecular oxygen determines HIF-1 activity. Under normal O2 levels (normoxia), 
prolyl hydroxylases (PHD) hydroxylate HIF-1α with molecular oxygen. This is recognized by E3 
ligase Von Hippel Lindau protein, which ubiquitinates HIF-1α for proteasomal degradation. 
Under low oxygen conditions (hypoxia), HIF-1α escapes degradation, heterodimerizes with HIF-
1β, translocates to the nucleus, and binds the hypoxia response element (HRE) to activate gene 
transcription. 
 
angiogenesis, glycolysis, and metastasis.14,15 While RNA interference technology 
targeted to the HIF mRNA can abrogate HIF-mediated transcription in a specific-manner, 
the technology is limited by issues of delivery and distribution.16,17 Instead, small 
molecules that bind the DNA binding site of HIF have been investigated for their 
transcriptional modulation, including a Py-Im polyamide targeted to the consensus 
hypoxia response element (HRE) 5’-NRCGTG-3’.18-22  Py-Im polyamides are a class of 
cell-permeable DNA-binding small molecules with programmable sequence-
specificity.23-28  They have been shown to localize in the nucleus, access chromatin, and 
bind DNA sequences with affinities and specificities comparable to endogenous 
transcription factors.29-32 
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The genome-wide transcriptional effects of a Py-Im polyamide N1 targeted to 5’-
WTACGW-3’ (structure Figure 5.2A) have been previously characterized by Nickols et 
al. using microarray technology.20 The global transcriptome pertubations due to N1 was 
assessed in the U251 glioblastoma cell line with desferrioxamine (DFO), an iron chelator, 
as a model of hypoxia. It was shown that N1 downregulates by >2 fold 69 genes, out of 
297 genes induced >4 fold by treatment with DFO. 20 In comparison, the same study 
found 244 genes were downregulated by >2 fold by siRNA for HIF-1α.20 This effect is 
potentially indicative of the greater sequence specificity of Py-Im polyamides in the 
variable regions of the HRE. The study by Nichols and coworkers observed correlation of 
transcriptional changes with HIF occupancy, as measured by PCR and chromatin 
immunoprecipiation (ChIP) at multiple loci.20 However, the interrogation of HIF 
occupancy was limited by the scope of the method. An alternative hypothesis for the 
mechanism of transcriptional modulation has been proposed, whereby hairpin polyamides 
disrupt RNA Pol II elongation of transcripts and cause degradation of the RNA Pol II 
large subunit.33 This chapter will describe the application of ChIP-seq to assess global 
HIF transcription factor occupancy and analyze genome-wide perturbation of HIF by 
hairpin polyamide 1 (Figure 5.2A and 5.2B). Polyamide 1 is targeted to the same DNA 
sequence and contains the same core aromatic amino acids, and only differs by the 
location of the amine on the butyric acid turn unit. This study will provide a basis for 
understanding the gene expression changes previously observed upon polyamide 
treatment relative to transcription factor displacement.  
 
ChIP-seq, the immunoprecipitation of DNA fragments associated with proteins 
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Figure 5.2  Structure of polyamides targeted to the 
hypoxia response element (HRE). A) Polyamide N1 
was used in a previous study of genome-wide gene 
expression. Polyamide 1, which differs in the 
placement of the amine highlighted in yellow, was 
used in the present study. B) Schematic diagram of 
polyamide 1 bound to a sequence-matched HRE 
sequence preventing HIF-1 binding and disrupting 
transcription. 
 
followed by next-generation sequencing, allows for the genomic mapping of binding 
events (Figure 5.3).34 Software is used to determine the binding sites of transcription 
factors from the enrichment patterns of derived from the sequencing and mapping of 
millions of DNA fragments.35 As the technology queries the entire genome, it eliminates 
the intrinsic bias of choosing PCR primers or probe sets of limited scope. By comparing 
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the number of DNA fragments immunoprecipiated per region between varying sample 
conditions, HIF occupancy can be compared under normoxic, hypoxic, and polyamide 1- 
treated conditions genome-wide. 
 
This chapter describes ChIP-seq adapted to assess HIF occupancy under true 
hypoxia, low oxygen. ChIP-seq was conducted as previously described,36 with 
modifications to accommodate the oxygen-dependent lability of HIF on DNA. Though 
DFO was used as a model of hypoxia in the microarray transcriptome analysis of N1 in 
induced U251 cells,20 its transcriptional effects differ from that of true hypoxia.37 DFO is 
an iron chelator that was found to function as a hypoxia mimic by chelating the catalytic 
iron in the PHD’s such that hydroxylation of HIF does not occur.38 This prevents 
proteasomal degradation of HIF but likely also has significant off-target effects. The 
differential expression profiles of “hypoxia” inducing agents reported by Poellinger and 
coworkers motivates the induction of HIF by 0.5% O2 hypoxia.37 Working in a 21% O2 
ambient environment presents a technical challenge of cross-linking HIF to DNA before 
O2 levels rise in the cells. It has been reported that HIF association on DNA reaches 
maximal levels at 0.5% O2 in 12.4 minutes.39 In the same study, they found that 
reoxygenation in ambient O2 resulted in HIF dissociation beginning at 2 minutes, and 
near complete dissociation by 16 minutes.39 Detailed procedures to create and maintain 
hypoxia and accomplish cross-linking in this timeframe are described in Materials and 
Methods. 
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Figure 5.3  Experimental scheme for ChIP-seq with samples prepared in hypoxia. Hypoxia is 
achieved by nitrogen displacement to 0.5% O2 in an incubator. Proteins on DNA are immediately 
cross-linked with formaldehyde. DNA is sheared and HIF-1α is enriched by immunoprecipitation. 
Eluted DNA is sequenced by next-generation sequencing and mapped to the human genome. 
Enriched samples are compared to background to find enriched peaks using appropriate analysis 
algorithms. 
 
5.2  Results 
U251 cells grown under three conditions were prepared for ChIP-seq: 1) untreated cells 
in normoxia (non-induced, NI); 2) untreated cells subject to 0.5% O2 hypoxia for 2 hours 
(hypoxia-induced, Id); and 3) cells treated with 1 µM of hairpin 1 for 48 hours prior to  
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Table 5.1  Sequenced reads categorization for background input samples and enriched 
immunoprecipitated (IP) samples.    
 
Samples Raw (millions) 
Quality filtered 
(millions) 
Unique 
(millions) 
Multiread 
(millions) 
NI input 14.6 9.0 (61%) 7.0 (78%) 0.6 (3%) 
Id input 20.1 12.0 (59%) 9.4 (79%) 0.7 (6%) 
1 input 35.6 20.3 (56%) 16.4 (81%) 1.3 (6%) 
NI IP 67.6 53.2 (79%) 31.0 (58%) 2.6 (5%) 
Id IP 5.8 3.6 (61%) 2.8 (78%) 0.2 (6%) 
1 IP 41.3 32.5 (79%) 18.8 (58%) 1.3 (4%) 
 
 
 0.5% O2 hypoxia for 2 hours (hypoxia-induced and treated with 1, 1). Chromatin was 
isolated and sheared, and a portion saved to serve as the input background control. DNA 
cross-linked to HIF was immunoprecipitated with an anti-HIF-1α primary antibody and a 
secondary antibody conjugated to magnetic beads. Immunoprecipitated DNA for each 
condition (NI_IP, Id_IP, 1_IP) as well as the input background controls (NI_input, 
Id_input, 1_input) was purified and submitted for sequencing on an Illumina Genome 
Analyzer IIx. The sequencing produced a range of 5.8 million to 67.6 million raw reads 
of 50 base pairs per sample (Table 5.1). The reads were then reduced through a quality 
filter and mapped to the human genome build 19 using the Bowtie algorithm.40 Of the 
reads passing the quality filter, 58-81% mapped to a unique genomic locus while the 
remaining sequences mapped to multiple loci or did not map. Only sequencing reads 
mapped to unique loci were used for further analysis. The Id_IP sample had the lowest  
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Figure 5.4  Motifs (A and B) of enriched sites discovered by the findall algorithm. Each motif 
was searched for matches at a 85% match threshold in the human genome and the 
immunoprecipitated sequences (IP regions), and its enrichment is shown as a rate per million base 
pairs. 85% match sequences were then used to generate a motif to compare to the original 
discovered motif.  
 
number of reads and the reduced sequencing depth results in coarse granularity of the 
data, but does not otherwise impact the data analysis, as measurements are normalized 
per million reads. 
 
Using the ERANGE commoncode program “findall”,41 we identified 
differentially enriched regions between the NI_IP and Id_IP samples, defined as 50% 
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increase upon hypoxia induction with at least 2 reads per million (RPM) in the induced 
condition. These identified sequence reads were then entered into the MEME motif 
finding algorithm. If enrichment of HIF-bound DNA was accomplished, we would expect 
to find the HRE consensus motif among the discovered motifs. Indeed, we found two 
discovered motifs (among 10 generated) that contained the HIF binding site motif 5’-
NACGTG-3’ (Figure 5.4A and 5.4B).21,22 Each of the motifs was then used to search the 
human genome and immunoprecipitated regions at a 85% match threshold to assess 
relative enrichment. The motif shown in Figure 5.4A was found at a rate of 2.4 RPM in 
the genome, whereas it was enriched to 1025.2 RPM in the HIF precipitated sequence. 
The motif shown in Figure 5.4B similarly occurred with 603.9 versus 0.66 RPM 
enrichment in the immunoprecipitated sample, greater than the genome in general. The 
similarity of the motif generated from the identified sequences at 85% threshold to the 
original search motif indicates that these sequences are reasonable matches to the motif in 
question. The identification of the HRE consensus sequence provides evidence that this 
ChIP-seq method detects HIF transcription factor enrichment on DNA. 
 
We next examined the unique reads mapped to genomic loci associated with 
genes under HIF transcriptional control. The CA9 promoter region has previously been 
interrogated by ChIP-qPCR and HIF occupancy observed to be reduced under polyamide 
N1-treated conditions.20 In the wigglegram shown Figure 5.5A, there is a peak upstream 
of the transcription start site in the Id_IP condition higher than in the NI_IP condition 
showing increased HIF occupancy under hypoxia induction. Further, we observe that the  
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Figure 5.5  Wigglegrams from immunoprecipitated sequences of non-induced (NI), hypoxia-
induced (Id), and polyamide 1-treated (1) samples mapped to the human genome. Enriched region 
highlighted in orange. A) CA9 gene, B) ENO1, C) PFKFB3, D) BNIP3, and E) VEGFA, which 
showed no enrichment in the promoter region. RefSeq gene map shown below wigglegrams with 
gene directionality. 
 
peak is reduced in the PA1-treated condition. This was observed for multiple genes under 
HIF control, including ENO1, PFKFB3, and BNIP3 (Figure 5.5B-D). Interestingly, a 
peak was not observed for VEGFA, though it was reported previousy with DFO 
induction. More replicates are necessary to determine whether this is a reproducible  
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Figure 5.6  Quantitation of sequence reads within a 150 base pair 
window of peaks identified by findall in the promoter regions of 
A) CA9, B) ENO1, C) PFKFB3, and D) BNIP3. Sequencing depth 
is normalized by reads per million (RPM). 
 
difference between DFO and hypoxia induction. The data supports identification of HIF 
enrichment at distinct loci in the promoter regions of HIF-controlled genes by this 
method. 
 
The differential HIF occupancy in this region can be further quantified by 
counting the number of mapped unique reads within a 150 base pair radius of the center 
of the peak (300 base pair window). Figure 5.6A-D shows the quantitation of the reads in 
a 300 base pair window around the peak discovered by findall for the genes in Figure 5.5. 
These loci were among those selected by the findall algorithm after a cutoff of 50% 
minimum increase of HIF occupancy upon induction. In fact, the CA9, PFKFB3, and 
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BNIP3 all show greater than 2-fold increase in HIF occupancy upon induction. These loci 
also show reduced occupancy with hairpin 1 treatment, down to near baseline levels for 
CA9 and ENO1 (Figure 5.6A and B). The decrease in HIF occupancy at these sites after 
polyamide treatment is a likely factor in reducing transcription at these loci. This study 
establishes that ChIP-Seq can be a valuable tool towards understanding genome-wide 
perturbations of HIF occupancy by Py-Im polyamides. 
 
5.3  Discussion 
The ChIP-seq method was employed in this exploratory study to assess genome-
wide HIF occupancy after induction with 0.5% O2 hypoxia. Detection of the HRE 
consensus sequence within the enriched regions suggests that the current method is 
sufficient for the detection of HIF. The diminution of the occupancy peaks in the 
promoter regions in the PA1-treated condition, in comparison to the hypoxia-induced 
condition, indicates this method will be competent to quantify perturbations to 
occupancy. Further study employing this method in biological replicates will lend 
statistical power to measurements of occupancy and may reveal global patterns of hairpin 
polyamide-mediated perturbations of HIF. Comparison with RNA Pol II occupancy, 
epigenetic marks, and other transcription factors may suggest mechanisms by which Py-
Im polyamides affect transcription. 
 
5.4  Materials and methods 
Py-Im polyamide synthesis. Hairpin polyamide 1 was synthesized by 
microwave-assisted, solid-phase synthesis on Kaiser oxime resin (Novabiochem) 
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according to previously described protocols.42,43 Purity and identity was verified by 
analytical HPLC and matrix-assisted laser desorption/ionization time-of-flight (MALDI-
TOF) mass spectrometry. MALDI-TOF: Expected 1394.5, Found 1394.1. 
ChIP-seq.  U251 cells were plated onto 3 square 500 cm2 plates (Corning) per 
condition at 2 million per plate in 80 ml of RPMI media (Gibco) and left to adhere 
overnight. Cells were untreated or treated with polyamide 1 for 48 hours prior to 
induction of hypoxia. Hypoxia was achieved by N2 displacement until 0.5% oxygen was 
measured on a Pro-Ox 110 (Biospherix) oxygen detector and maintained for 2 hours.  
Phosphate buffered saline (PBS, Gibco) was de-gassed in vacuo and 
formaldehyde added to 1% by volume. The fixation solution was aliquoted 40 ml per 
sample into 50 ml falcon tubes and pre-equilibrated to 0.5% O2 for at least 30 minutes. 
Once the 2 hour induction period was complete, the hypoxia chamber was opened and the 
media for all samples were immediately dumped. The uncovered square plates were 
stacked at an offset angle to allow quick addition of the fixation solution. All samples 
were in the formaldehyde fixation solution within 90 seconds of removal from the 
hypoxia chamber and fixed for 15 min on a rotary shaker. After fixation, the cells were 
washed with cold PBS and 3 ml of 2.5 M glycine for 5 minutes and again washed with 
cold PBS.  
Previously established protocols were followed hereafter.34,36 In brief, nuclei were 
isolated from Farnham Lysis Buffer containing proteases, and resuspended in RIPA 
buffer. Chromatin was sonicated with a Branson Digital Sonifier over 25 cycles in a dry 
ice/EtOH bath, 30 seconds at a time. DNA was sheared to approximately 250 base pair 
fragments. Samples were centrifuged at 4 ºC at 14000 RPM and the supernatant collected 
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and quantitated with Bradford’s reagent. A fraction was saved as the background input 
sample. The previous day, anti-mouse magnetic beads (Dynabeads) were washed with 
PBS containing BSA and incubated overnight at 4 ºC with HIF-1α antibody (NB100-105, 
Novus Biologicals). The magnetic beads were washed of unconjugated antibody and 
incubated with 1 mg of protein overnight at 4 ºC. Immunoprecipitated DNA was eluted, 
extracted by phenol/CHCl3/isoamyl alcohol, and purified using a Qiagen clean up kit. 
Isolated DNA was quantified by Qubit (Life Technologies) and submitted for sequencing. 
Sequencing data was analyzed using freely available software as described above. 
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